β遮断薬のすべて

出版社: 先端医学社
著者:
発行日: 2000-09-20
分野: 薬学  >  薬物学
ISBN: 9784884070113
電子書籍版: 2000-09-20 (第1版第1刷)
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,475 円(税込)

商品紹介

本企画「β遮断薬のすべて」として現状での医学的水準からβ遮断薬を多面的に評価し、その臨床応用を述べることは時宣を得たものといえる。(序文より)

目次

  • 表紙
  • 執筆者一覧
  • 目次
  • Part 1 / β遮断薬のプロファイル
  • 1. β遮断薬開発の歴史
  • はじめに
  • [1] β遮断薬の開発とプロプラノロールの登場
  • [2] ISAを有するピンドロールの開発とその後
  • [3] β1選択性β遮断薬の開発と適応の拡大
  • [4] αβ遮断薬ラベタロールからカルベジロール
  • [5] わが国におけるβ遮断薬の開発状況
  • おわりに
  • 2.β受容体を介する情報伝達
  • はじめに
  • [1] βアドレナリン受容体の構造
  • 1) β受容体蛋白
  • 2) G蛋白
  • 3) アデニル・シクラーゼ
  • [2] アドレナリン受容体のシグナル伝達
  • [3] アドレナリン受容体の調節
  • 1) 脱感作現象
  • 2) modified ternary complex model
  • 3) クロストーク現象
  • 4) 遺伝子多型
  • [4] 遺伝子操作マウスでの成績
  • [5] アドレナリン受容体の各種病態への関与
  • おわりに
  • 3. β遮断薬の分子機構
  • はじめに
  • [1] βアドレナリン受容体の基本的性質
  • [2] βアドレナリン受容体の構造とリガンド結合部位
  • [3] βアドレナリン受容体ノックアウトマウス-βアドレナリン受容体の役割について-
  • [4] βアドレナリン受容体脱感作
  • [5] 新しいβ遮断薬の可能性
  • おわりに
  • 4. β遮断薬の付加的作用
  • はじめに
  • [1] 内因性交感神経活性(ISA)
  • [2] 抗酸化作用
  • [3] 心筋に対する付加的作用
  • 1) 膜安定化作用(MSA)
  • 2) 心筋イオンチャネルに対する作用
  • 3) 心筋保護作用
  • [4]血管に対する付加的作用
  • 1) 血管拡張作用
  • 2) 抗動脈硬化作用
  • [5] その他の付加的作用
  • 1) 抗血栓作用
  • 2) 赤血球に対する作用
  • 3) 甲状腺ホルモンに対する作用
  • おわりに
  • 5. β遮断薬の薬物動態
  • [1] β受容体の分類と臓器分布および生理機能
  • [2] β遮断薬の特徴
  • [3] β遮断薬の薬物動態
  • おわりに
  • 6.β遮断薬の分類
  • はじめに
  • [1] β遮断薬の作用
  • 1) β1選択性(心選択性)
  • 2) 内因性交感神経活性(ISA:部分的β刺激作用)
  • 3) α遮断作用など血管拡張作用
  • 4) 脂容性
  • 5) 膜安定性
  • 6) inverse agonismなど, その他の作用
  • [2] 世代別分類
  • おわりに
  • 7. β遮断薬の降圧作用
  • はじめに
  • [1] β遮断薬の降圧機序と適応
  • [2] 降圧薬としてのβ遮断薬の特徴
  • 1) β1(心) 受容体選択性
  • 2) 内因性交感神経活性(ISA)
  • 3) α遮断作用
  • 4) 直接血管拡張作用
  • おわりに
  • Part 2 / β遮断薬の臓器別作用
  • 1. β遮断薬の心臓(心筋, 冠, 伝導) に対する作用
  • はじめに
  • [1] 心臓におけるβ受容体とβ遮断薬
  • [2] β遮断薬の電気生理学的効果
  • [3] 心疾患における心筋細胞内情報伝達異常とβ遮断薬
  • おわりに
  • 2.β遮断薬の血管・血管内皮に対する作用
  • はじめに
  • [1] 血管平滑筋に対するβ遮断薬の作用
  • 1) β遮断薬としての作用
  • 2) Ca2}+拮抗作用をもつβ遮断薬
  • 3) ニトロ基をもつβ遮断薬
  • [2] 血管内皮細胞への作用
  • 1) NO産生増加作用
  • 2) PGI2合成促進作用
  • 3) 内皮細胞からのET-1産生抑制作用
  • [3] 動脈硬化血管に対する作用
  • 1) 脂質に対する影響
  • 2) 動脈硬化血管に対する作用
  • 3) 抗酸化作用
  • [4] 血管リモデリングへの作用
  • おわりに
  • 3. β遮断薬の脳循環に対する作用
  • はじめに
  • [1] 脳血管の交感神経支配について
  • [2] β遮断薬の脳循環に対する作用
  • 1) 急性投与
  • 2) 慢性投与
  • 3) β遮断薬と認知機能
  • [3] β遮断薬による脳卒中一次予防
  • おわりに
  • 4. β遮断薬の腎臓に対する作用
  • はじめに
  • [1] β遮断薬の腎臓に対する作用
  • 1) プロプラノロール(非心選択性, ISAなし, 胆汁排泄)
  • 2) ピンドロール(非心選択性, ISAあり)
  • 3) アセブトロール(心選択性, ISAあり)
  • 4) ナドロール(非心選択性, ISAなし)
  • 5) 心選択性を有するβ遮断薬
  • [2] β遮断薬の腎臓内作用
  • [3] 腎血管拡張性β遮断薬
  • [4] β遮断薬の体液量と電解質に与える影響
  • [5] α1β遮断薬について
  • 1) ラベタロール
  • 2) カルベジロール
  • 3) アロチノロール
  • [6] 長期間の使用でのβ遮断薬の腎機能に及ぼす影響
  • おわりに
  • 5. β遮断薬の肝・膵臓に対する作用
  • はじめに
  • [1] 肝-門脈圧への影響
  • 1) 肝硬変症における門脈血行動態
  • 2) 門脈圧亢進症における各種β遮断薬の効果
  • [2] 膵-糖代謝への影響
  • 1) 低血糖誘発
  • 2) インスリン分泌への影響
  • 3) インスリン感受性への影響
  • おわりに
  • Part 3 / 血圧調節因子とβ遮断薬
  • 1. 血圧調節因子とβ遮断薬
  • はじめに
  • [1] ナトリウム利尿ペプチドとβ遮断薬
  • [2] エンドセリンとβ遮断薬
  • [3] 一酸化窒素とβ遮断薬
  • [4] β遮断薬とカテコールアミン
  • [5] レニン・アンジオテンシン系とβ遮断薬
  • おわりに
  • Part 4 / 高血圧
  • 1. 第一選択薬としてのβ遮断薬の位置づけ
  • はじめに
  • [1] 最近の管理指針にみるβ遮断薬の評価
  • [2] β遮断薬の適応となる病態および合併症
  • 1) 冠動脈疾患 / 狭心症
  • 2) 心筋梗塞後 / 心不全
  • 3) 糖尿病
  • [3] β遮断薬の禁忌 / 悪影響を与える病態
  • おわりに
  • 2. 軽症高血圧におけるβ遮断薬の位置づけ
  • はじめに
  • [1] 軽症高血圧の定義
  • [2] β遮断薬の臓器保護作用
  • [3] β遮断薬の適応患者と副作用
  • おわりに
  • 3. 中等症, 重症高血圧におけるβ遮断薬の位置づけ
  • はじめに
  • [1] grade 3の高血圧患者
  • [2] 虚血性心疾患を合併した患者
  • [3] 心不全を合併した患者
  • [4] 脳卒中を合併した患者
  • [5] 糖尿病を合併した患者
  • [6] 高齢者
  • おわりに
  • 4. 二次性高血圧とβ遮断薬
  • はじめに
  • [1] 腎実質性高血圧とβ遮断薬
  • [2] 腎血管性高血圧
  • [3] 褐色細胞腫
  • [4] 原発性アルドステロン症
  • [5] 妊娠に伴う高血圧
  • [6] その他の高血圧
  • 1) 自己免疫疾患に伴う高血圧
  • 2) 大動脈弁閉塞不全症, 甲状腺機能亢進症
  • おわりに
  • 5. 若年者高血圧とβ遮断薬
  • はじめに
  • [1] 血圧のトラッキング
  • [2] 若年者の血圧と肥満の関連
  • [3] 将来の血圧の予知と血行動態
  • [4] 若年者の血圧の時代的推移
  • [5] 若年者の高血圧の診断
  • [6] 若年者の白衣高血圧
  • [7] 若年者の高血圧における代謝異常
  • [8] 若年者の高血圧の管理
  • 1) 非薬物治療
  • 2) 薬物治療
  • おわりに
  • 6. 老年者高血圧とβ遮断薬
  • はじめに
  • [1] 老年者高血圧の特徴とβ遮断薬
  • [2] β遮断薬の分類
  • [3] 老年者高血圧治療におけるβ遮断薬の位置づけ
  • 1) 老年者高血圧におけるβ遮断薬の降圧効果と有用性
  • 2) 老年者高血圧を対象にβ遮断薬を用いておこなわれた大規模臨床試験
  • [4] β遮断薬の心保護作用
  • [5] 老年者高血圧に対するβ遮断薬治療
  • 7. 24時間生体リズムとβ遮断薬
  • はじめに
  • [1] β遮断薬の薬剤特性と24時間血圧
  • 1) ISAを有するβ遮断薬が24時間血圧変動に及ぼす影響
  • 2) ISAを有さないβ遮断薬が24時間血圧変動に及ぼす影響
  • 3) α遮断作用を併せ持つβ遮断薬が24時間血圧変動に及ぼす影響
  • [2] β遮断薬の時間治療への応用
  • おわりに
  • Part 5 / 合併症を伴った高血圧とβ遮断薬
  • 1. 虚血性心疾患を伴った高血圧とβ遮断薬
  • はじめに
  • [1] 虚血性心疾患を合併した高血圧β遮断薬治療の臨床的エビデンス
  • 1) 虚血性心疾患におけるβ遮断薬の有効性
  • [2] 作用機序からみたβ遮断薬の利点
  • [3] β遮断薬の適応と薬剤選択の実際
  • おわりに
  • 2. 心肥大を伴った高血圧とβ遮断薬
  • はじめに
  • [1] 左室肥大の定義と診断法
  • [2] 左室肥大の頻度
  • [3] 左室肥大を生ずる原因
  • [4] 左室肥大の病的意義
  • [5] 降圧療法と心筋肥大の退縮
  • [6] メタアナリシスにみた降圧療法とLVmass退縮
  • おわりに
  • 3. 不整脈を伴った高血圧とβ遮断薬
  • はじめに
  • [1] 不整脈と自律神経
  • 1) 交感神経活動
  • 2) 副交感神経活動
  • [2] 心拍変動と自律神経
  • [3] 抗不整脈薬と自律神経機能
  • [4] 不整脈を伴う高血圧とβ遮断薬
  • [5] 抗不整脈薬の併用療法
  • [6] 催不整脈作用
  • おわりに
  • 4. 心不全を伴った高血圧とβ遮断薬
  • はじめに
  • [1] 高血圧性心不全の病態
  • [2] 高血圧性心不全の治療におけるβ遮断薬の役割
  • [3] 心不全におけるカルベジロールの有効性
  • おわりに
  • 5. 腎障害を伴った高血圧とβ遮断薬
  • はじめに
  • [1] 腎と高血圧
  • [2] 腎保護的降圧とその指標
  • [3] 腎障害合併高血圧とβ遮断薬
  • おわりに
  • 6.脳血管障害を伴った高血圧とβ遮断薬
  • はじめに
  • [1] 脳梗塞慢性期の脳循環動態
  • [2] 高血圧治療と脳血管障害の再発
  • [3] 慢性期脳梗塞の血圧管理
  • 1) 降圧日標レベル
  • 2) 降圧薬の選択
  • [4] β遮断薬と悩卒中
  • 1) 脳卒中の発症予防
  • 2) 脳卒中の再発予防
  • 3) 脳循環への効果
  • おわりに
  • 7. 糖尿病を伴った高血圧とβ遮断薬
  • はじめに
  • [1] β遮断薬のインスリン抵抗性に及ぼす影響
  • 1) 糖代謝に及ぼす影響
  • 2) 脂質代謝に及ぼす影響
  • [2] β遮断薬と低血糖
  • [3] 虚血性心疾患を伴った糖尿病患者におけるβ遮断薬の意義
  • おわりに
  • 8. 高脂血症・動脈硬化を伴った高血圧とβ遮断薬
  • はじめに
  • [1] 交感神経系と脂質代謝
  • [2] β遮断薬の血清脂質に対する影響
  • [3] β遮断薬と動脈硬化性疾患
  • [4] β遮断薬と抗酸化作用
  • [5] 動脈硬化を伴った高血圧の治療
  • おわりに
  • Part 6 / 虚血性心疾患治療薬としてのβ遮断薬
  • 1. 心筋梗塞急性期治療薬としてのβ遮断薬
  • はじめに
  • [1] AMI急性期β遮断薬の適応と使用法
  • [2] これまでのエビデンス
  • 1) 再灌流療法以前
  • 2) 再灌流療法以降
  • [3] 再灌流時代におけるβ遮断薬早期投与の意義
  • [4] ST上昇を伴わないAMI
  • おわりに
  • 2. 心筋梗塞慢性期治療薬としてのβ遮断薬
  • はじめに
  • [1] β遮断薬の心筋梗塞二次予防における有効性
  • [2] 心筋梗塞患者の慢性期におけるβ遮断薬使用の現状
  • [3] 心筋梗塞患者の慢性期におけるβ遮断薬適応の拡大
  • [4] 再灌流療法とβ遮断薬の併用
  • おわりに
  • 3. 狭心症治療薬としてのβ遮断薬
  • はじめに
  • [1] 狭心症について
  • 1) 病因
  • 2) 臨床像と分類
  • 3) 発症機序
  • 4) 無症候性心筋虚血
  • [2] 狭心症に伴う合併症
  • 1) 心室機能障害
  • 2) 不整脈
  • [3] β遮断薬の役割
  • 1) 基本的な治療方針
  • 2) β遮断薬の位置づけ
  • 3) 薬理作用と適応
  • おわりに
  • 4.無症候性心筋虚血とβ遮断薬
  • はじめに
  • [1] SMIの機序
  • [2] SMIの分類と診断
  • 1) 新しい検査法
  • [3] SMIの治療
  • [4] SMIへの薬物治療:β遮断薬の有用性は?
  • 1) β遮断薬の有用性
  • 2) Ca拮抗薬の有用性
  • 3) Ca拮抗薬とβ遮断薬の比較
  • 4) 今後の方向性
  • Part 7 / 不整脈治療薬としてのβ遮断薬
  • 1. 不整脈治療薬としてのβ遮断薬
  • はじめに
  • [1] 電気生理学的作用
  • [2] 上室性不整脈
  • 1) 洞性頻脈
  • 2) 心房性頻拍
  • 3) 心房細動
  • 4) 心房粗動
  • 5) 房室結節リエントリー性頻拍
  • 6) 副伝導路を介する房室回帰性頻拍
  • [3] 心室性不整脈
  • 1) 心室性期外収縮・非持続性心室頻拍
  • 2) カテコールアミン誘発性心室性不整脈
  • 3) 反復性単形性心室頻拍
  • 4) 持続性単形性心室頻拍
  • 5) 多形性心室頻拍・心室粗動
  • 6) QT延長症候群
  • 7) 心室細動
  • [4] 副作用
  • Part 8 / 心不全治療薬としてのβ遮断薬
  • 1. 心不全治療薬としてのβ遮断薬
  • はじめに
  • [1] 心不全時の交感神経活動とβ遮断薬の作用機序
  • 1) 心不全時の交感神経活動
  • 2) 交感神経興奮による心筋不全悪化の機序
  • 3) β遮断薬が有効である機序
  • [2] β遮断薬療法の適応
  • [3] 慢性心不全に対するβ遮断薬の投与方法
  • 1) 投与方法
  • 2) 投与時の観察項目と注意点
  • [4] β遮断薬治療の臨床試験成績
  • おわりに
  • Part 9 / その他の疾患治療薬としてのβ遮断薬
  • 1. その他の疾患治療薬としてのβ遮断薬
  • はじめに
  • [1] 肥大型心筋症
  • [2] 先天性QT延長症候群
  • [3] 神経調節性失神
  • [4] 甲状腺機能亢進症
  • [5] 門脈圧亢進症
  • [6] 本態性振戦
  • [7] 緑内障
  • おわりに
  • Part 10 / 併用治療におけるβ遮断薬
  • 1. 高血圧治療薬との併用におけるβ遮断薬
  • はじめに
  • [1] WHO-ISHのガイドラインが推奨している組み合わせ
  • 1) β遮断薬と利尿薬の併用
  • 2) β遮断薬とジヒドロピリジン系Ca拮抗薬の併用
  • 3) β遮断薬とα遮断薬の併用
  • [2] その他の組み合わせ
  • 1) β遮断薬とACE阻害薬の併用
  • 2) β遮断薬と非ジヒドロピリジン系Ca拮抗薬の併用
  • 3) β遮断薬とその他の高血圧治療薬の併用
  • おわりに
  • 2. 虚血性心疾患治療薬との併用におけるβ遮断薬
  • はじめに
  • [1] 抗狭心症薬の種類と特徴
  • 1) 硝酸薬
  • 2) Ca拮抗薬
  • 3) β遮断薬
  • [2] 心筋虚血発作の病態からみたβ遮断薬選択の意義
  • 1) 無症候性心筋虚血発作の意義
  • 2) 心筋虚血発作の出現機序
  • 3) 心筋虚血発作の日内分布
  • [3] 虚血発作に対する抗狭心症薬の併用効果
  • 1) Ca拮抗薬とβ遮断薬の併用
  • 2) 硝酸薬とβ遮断薬の併用
  • 3) カルベジロールの抗狭心症作用
  • 4) ACC / AHA / ACP-ASIM合同委員会による慢性安定狭心症患者のガイドライン
  • おわりに
  • 3. 不整脈治療薬との併用におけるβ遮断薬
  • はじめに
  • [1] 併用療法の概念・適応
  • [2] 理論的背景
  • [3] β遮断薬とほかの抗不整脈薬との併用の実際
  • 1) 心室期外収縮に関する自験例
  • 2) 心室期外収縮に関する諸家の報告
  • 3) 心室頻拍に対する併用療法
  • 4) その他の不整脈に対する併用療法
  • [4] 併用療法の問題点
  • おわりに
  • Part 11 / β遮断薬とQOL
  • 1. β遮断薬のQOLへの影響
  • はじめに
  • [1] QOLに影響を与えるβ遮断薬の副作用
  • [2] β遮断薬による降圧療法のQOLへの影響
  • 1) プロプラノロール
  • 2) アテノロール
  • 3) その他のβ遮断薬
  • [3] 心不全, 狭心症治療におけるβ遮断薬
  • おわりに
  • 2. β遮断薬のストレスへの影響
  • はじめに
  • [1] β遮断薬の中枢作用
  • [2] β遮断薬のストレス反応への影響
  • 1) ストレス状態への影響
  • 2) ストレスに対する心血管反応の影響
  • おわりに
  • Part 12 / β遮断薬使用上の注意点
  • 1. β遮断薬の副作用とその対策
  • はじめに
  • [1] β受容体の遮断による副作用
  • 1) 心不全
  • 2) 徐脈
  • 3) 末梢血管への作用
  • 4) 離脱症候群
  • 5) 呼吸器系
  • 6) 糖・脂質代謝
  • 7) 腎機能
  • 8) 電解質
  • 9) 中枢神経・性機能
  • 10) 周産期での副作用
  • [2] β受容体の遮断と直接関係しない副作用
  • 1) 発疹
  • 2) 線維性腹膜炎
  • 3) 白血球減少, 血小板減少
  • おわりに
  • 2. β遮断薬の禁忌
  • はじめに
  • [1] β1遮断作用による禁忌
  • 1) 徐脈, 房室ブロック, 心不全
  • [2] β2遮断作用による禁忌
  • 1) 慢性閉塞性肺疾患, レイノー症状, 閉塞性動脈硬化症
  • 2) 糖尿病
  • 3) その他
  • 4) 老年者高血圧
  • 5) 褐色細胞腫
  • おわりに
  • 3. β遮断薬の薬物相互作用
  • はじめに
  • [1] β遮断薬の薬理学的相違
  • [2] β遮断薬とほかの降圧薬との相互作用
  • 1) β遮断薬と利尿薬
  • 2) β遮断薬とCa拮抗薬
  • 3) β遮断薬とACE阻害薬
  • 4) β遮断薬とほかの降圧薬の組み合わせ
  • [3] β遮断薬と降圧薬以外の循環器疾患治療薬との相互作用
  • A. ジギタリス製剤
  • B. 抗不整脈薬
  • C. ジピリダモール
  • [4] β遮断薬と代謝性疾患治療薬
  • A. 高脂血症治療薬
  • B. 血糖降下薬
  • C. グルカゴン
  • [5] β遮断薬とNSAIDs
  • [6] β遮断薬と呼吸器疾患治療薬
  • A. テオフィリン
  • B. アドレナリン
  • C. イソプロテレノール
  • [7] β遮断薬と消化器疾患治療薬
  • A. 制酸薬
  • B. H2受容体拮抗薬
  • [8] β遮断薬と感染症治療薬
  • A. ペニシリン
  • B. アンピシリン
  • C. シプロフロキサシン
  • D. リファンピシン
  • [9] β遮断薬と中枢神経作用薬・神経科領域薬
  • A. ベンゾジアゼピン系
  • B. メジャートランキライザー
  • C. カルバマゼピン
  • D. マプロチリン
  • おわりに
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 / β遮断薬のプロファイル

P.29 掲載の参考文献
1) Dixon RA, Kobilka BK, Strader DJ et al:Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature 321:75-79, 1986
2) Krupinski J, Coussen F, Bakalyar HA et al:Adenylcyclase amino acid sequence:possible channel-or transporter-like structure. Science 244:1558-1564, 1989
3) Xiao RP, Ji X, Lakatta EG et al:Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive Gprotein in cardiac myocytes. Mol Pharmacol 47:322-329, 1995
4) Jurevicius J, Fischmeister R:cAMP compartmentation is responsible for a local activation of cardiac Ca2 channels by β-adrenergic agonists. Proc Natl Acad Sci USA 193:295-299, 1996
5) Gauthier C, Tavernier G, Charpentier F et al:Functional β3-adrenoceptor in human heart. J Clin Invest 98:556-562, 1996
7) Milano CA, Allen LF, Rockman HA et al:Enhanced myocardial function in transgenic mice overexpressing the β2-adrenergic receptor. Science 264:582-586, 1994.
8) Bond RA, Leff P, Johnson TD et al:Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor. Nature 374:272-276, 1995
9) Yoshikawa T, Port JD, Asano K et el:Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 19 (suppl B):S8-S16, 1996
10) Port JD, Hadcock JR, Malbon CC et al:Cross-regulation between G-protein-mediated pathways. J Biol Chem 1267:8468-8472, 1992.
11) Liggen SB, Wagoner LE, Craft LL et al:The Ile 164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102:1532-1539, 1998
12) Engelhardt S, Hein L, Wiesmann F et al:Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064, 1999
13) Koch WJ, Rockman HA, Samama P et al:Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or beta ARK inhibitor. Science 268:1350-1353, 1995
14) Rockman HA, Choi DJ, Rahman NU et al:Receptor specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA 93:9954-9959, 1996
15) Rockman HA, Chien KR, Choi DJ et al:Expression of a β-adrenergic receptor kinase I inhibitor prevents the development or rnyocardial failure in genetargeted mice. Proc Natl Acad Sci USA 95:7000-7005, 1998
17) Bristow MR, Minobe W, Rasmussen R et al:β-Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 89:803-815, 1992
19) Liang C, Rm TH, Sullebarger JT et al:Decreased adrenergic neuronal uptake activity in experimental right heart railure. J Clin Invest 84:1267-1275, 1989
20) Anzai T, Yoshikawa T, BaBa A et al:Mvocardial synlpathetic denervation prevents channber-specific alteration of β-adrenergic transmembrane signaling in heart failure. J Am Coll Cardiol 28:1314-1322, 1996
21) Communal C, Singh K, Pimentel DR et al:Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 98:1329-B34, 1998
22) Yamazaki T, Komuro I, Zou Y et al:Norepinephrine induces the raf-1 kinase/mitogen activated protein kinase cascade through both α1-and β-andrenpceptors. Circulation 95:1260-1268, 1997
P.37 掲載の参考文献
1) Alexander SPH, Petwcs JA:Adrenoceptors (β-adrenoceptors). Trend Pharmacol Sci 19991 Receptor & ion channel nomenclature supplement:13-14, 1999
2) Hoffman BB, Lefkowtz RJ, Taylor P:Neurotransmission:the autonomic and somantic Motor nervous system. In:The Pharmacological Basis of the Therapeutics. ed by Hardman JG, Limbird LE, McGraw-Hill, New York, 1996, pp105-139
3) Dzimiri N:Regulation of β-adrenoceptor signaling in cardiac function and disease. Pharmacol Review 51:465-501, 1999
4) Sleinberg SF:The molecular basis for distinct β-adrenergic receptor subtype actions in cardio-myocytcs. Circ Res 85:1101-1111, 1999
5) Gauthier C, Tavenlier G, Charpentier F et al:Functional β3-adrenoceptor in the human Heart. J Clin Invest 98:556-562, 1996
6) Gauthier C, Leblais V, Kobzik L et al:The negative inotropic effect of β3-adrenoceptor stimulation is mediated by activtition of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102:1377-1384, 1998
7) Kumann AJ, Preitner F, Sarscro D et al:(-)-CGP 12177 causes cardiostimulation and binds to cardiac putative β4-adrenoceptors in both wild-type and β4-adrenoceptor knockout mice. Mol Pharmacol 53:670-675, 1998
8) Castelano M, Bohm M:The cardiac β-adrenoceptor-mediated signaing Pathway and its alterations in Hypertensive heart disease. Hypertens 29:715-722, 1997
9) Savarese TM, Fraser CM:In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receplors. Biochem J 283:1-1992.
10) Strader CD, Sigal IS, Candelorc MR et al:Conserved aspartic acid residues 79 and 113 of the β-adrencrgic receptor have different roles in receptor function. J Biol Chem 1263:10267-10271, 1988
11) Strader CD, Candelore MR, Hill WS et al:A single amino acid substitution in the β-adrenergic receptor promotes partial agonist activity frorn antagonists. J Biol Chem 264:16470-16477, 1989
12) Strader CD, Cmdelore MR, Hill WS et al:Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J Biol Chem 264:13572-13578, 1989
13) Tota MR, Candelore MR, Dixon RA et al:Biophysical and genetic analys is of the ligand-binding siteof the βadrenoceptor. Trend Pharmacol Sci 12:4-6, 1991
15) Strader CD, Sigal IS, Dixon RAF:Structural basis of β3-adrenoceptor recetor function. FASEB J 3:1825-1832, 1989
16) Dohlman HG, Caron MG, DeBlasi A et al:Role of extracellular disulfide-bonded cysteines in the ligand binding function of thc β2-adrenergic receptor. Biochemistry 29:2335-2342, 1990
17) Strosberg AD, Pietr-Rouxel F:Function and regulation of the β3-adrenoceptor. Trend Pharmacol Sci 17:373-381, 1996
18) Hoffman BB, Lefkowitz RJ:Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In:The Pharmacological Basis of the Therapeutics, ed by Hardman JG, Limbird LE, McGraw-Hill, New York, 1996, pp199-248
19) Ruffolo RR, Feuerstein GZ, Ohlstein EH:Recent observations with β-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. Am J Hypertens 11:9S-14S, 1998
20) Jasper JR, Insel PA:Evolving concepts of partial agonism. The β-adrenergic receptor as a paradigm. Biochem Pharmacol 43:119-130, 1992
21) Frielle T, Daniel KW, Caron MG et al:Structural basis of β-adrc-energic receptor subtype specificity studied with chimeric β1/β2-adrenergic receptors. Proc Natl Acad Sci USA 85:9494-9498, 1988
22) Wieland K, Zuurmond HM, Krasel C et al:Involvement of Asn-293 in stereospecific agonist recognition and in activation of the β2-adrenergic receptor. Proc. Natl Acad Sci USA 493:9276-9281, 1996
23) Isogaya M, Sugimoto Y, Tanimura R et al:Binding pockets of the β1-and B2-adrenergic receplors for subtype-selective agonists. Mol Pharmacol 56:875-885, 1999
24) Rohrer DK, Dcsai KH, Jasper JR et al:Targeted disruption of the mouse β1-adrenergic receptor gene:developmental and cardiovascular effects. Proc Natl Acad Sci USA 93:7375-7380, 1996
25) Rohrer DK, Schauble EH, Desai KH et al:Alterations in dynamic heart rate control in theβ1-adrenregic receptor knockout mouse. Am J Physiol 274:H1184-H1193, 1998
26) Chruscinski AJ, Rohrer DK, Schauble E et al:Targeted disruption of the β2-adrenergic receptor gene. J Biol Chem 274:16694-16700, 1999
28) Susulic VS, Frederich RC, Lawitts J et al:Targeted disruption of the β3-adrenergic receptor gene. J Biol Chem 1270:29483-29492, 1995
29) Hausdorff WP, Caron MG, Lefkowitz RJ:Turning off the signal:desensitization of β-adrenergic rec-ptor function. FASEB J 4:2881-2889, 1990
30) Krupnick JG, Bevonic JL:The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319, 1998
31) Bunemann M, Hosey MM:G-protein coupled receptor kinases as modulators of G-protein signaling. J Physiol 517:5-23, 1999
32) Ungerer M, Bohm M, Elce JS et al:Altered expression of β-adrenergic receptors in the failing human heart. Circulation 87:454-463, 1993
33) Bristow MR:β-Adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569, 2000
34) Packer M:β-Blockade in heart failure. Basic concepts and clinical results. Am J Hypertens 11:23S-37S, 1998
35) Zhang YC, Kimura B, Shen L et al:New β-blocker. Prolonged reduction in high blood pressure with β antisense oligodeoxynucleotides. Hyrpetens 35:219-224, 2000
37) Ishikawa Y, Katsushika S, Chen L et al:Isolation and characterization of a novel cardiac adenylylcyclase cDNA. J Biol Chem 267:13553-13557, 1992
40) Ebina T, Kawabe J, Toya Y et al:Isoform-specific regulation of adenylylcyclase by oxidized catecholamines. J Mol Cell Cardiol 29:1247-1254, 1997
P.43 掲載の参考文献
1) 秋田穂束:循環器疾患の薬物療法, β遮断薬・循環器NOW 15, 横山光宏編, 南江堂, pp179-186, 1997
2) 松田康章, 秋田穂束:β遮断薬の多重作用. Cardiologist 4:583-589, 1999
3) Murray KT, Reilly C, Koshakji RP et al:Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest 85:836-842, 1990
4) Cheng J, Miwa R, Kamiya K et al:Carvedilol blocks thc repolarizing K currents and the L-type Ca current in rabbit ventricular myocytes. Eur J Pharmacol 376:189-201, 1999
5) Watts SW, Fink GD, Silver PJ et al:Interaction of the adrenergic receptor antagonist bucindolol with serotonergic receptors. J Cardiovasc Pharmacol 35:29-36, 2000
6) Salvetti A, Leonetti G, Bernini GP et al:Antihypertensive and renal effects of tertatolol. a new beta-blocking agent, in hypertcnsive patients. Am J Nephrol 6 (suppl 2):S45-S49, 1986
7) Setoguchi M, Ohya Y, Abe I et al:Inhibitory action of betaxolol, a β1-selective adrenoceptor antagonist. on voltage-dependent calcium channels in guinea-pig artery and vein. Br J Pharmacol 115:198-202, 1995
8) Cockroft JR, Chowienczyk PJ, Brett SE et al:Nebivolol vasodilates human forearm vasculature:Evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 274:1067-1071, 1995
9) 秋田穂束, 横山光宏:β遮断薬と非ステロイド系消炎鎮痛薬, 松田重三編, 医歯薬出版(印刷中)
10) Beckman ML, Gerber JG, Byyny RL et al:Propra-nolol increases prostacyclin synthesis in patients with essential hypertension. Hypertension 12:582-588, 1988
12) Kaplan NM, Manuck SB:Antiatherogenic effects of, 9-adrenergic blocking agents:Theoretical, experimental, and epidemiologic considerations. Am Heart J 128:1316-1328, 1994
13) Frishman WH:Multifactorial actions or beta-adrenergic blocking drugs in ischemic heart disease:current concepts. Circulation 67 (suppl I):S11-S18, 198
P.49 掲載の参考文献
1) Gilman AG, Rall TW, Nies AS et al:Goodman and Gilmans The Pharmacological Basis of Therapeutics eighth edition, Pergamon Press, 1990
2) 戸田昇, 安孫子保:循環系治療薬の作川メカニズム, 南江堂, 1998
3) 水島裕, 宮本昭IE:今日の治療薬99, 南江堂, 1999
4) van Zwieten PA:Different properties ofβ-adrenoceptor blockers:characteristics of bopindolol In:The Position of Bopindolol, a New β-Blocker' Proceedings, Round Table Conference, Amsterdam. May 23, 1986. ed by van Zwieten PA, Royal Society of Medicine Services, London, New York 1987, pp1-11
5) Johnsson G, Regardh CG:Clinical pharmacokinetics of β-adrenoceptor blocking drugs. Clin Pharmacokinet 1:233-263, 1976
6) Feucrstein G, Yue TL, Ruffolo RR Jr et al:Carvedilol Update:Amultiple action antihypertensive agent with antioxidant activity and the Potential for myocardial and vascular protection. Drugs of Today 30 (suppl 1):S1-S20, 1994
P.54 掲載の参考文献
1) Brown MJ, Brown DC, Murphy MB:Hypokalemia from beta β-receptor stimulation by circulating epinephrine. N Eng J Med 309:1414-1419, 1983
2) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blocker:importance ancillary properties. Prog Cardiovasc Dis 39:445-456, 1997
3) Eichhom EJ, Hialmarson A:β-blocker treatment for chronic heart failure. The frog prince. Circulation 90:2153-2156, 1994
4) Frishman WH:Pindolol:a new β-adrenoreceptor antagonist with partial agonist activity. N Eng J Med 308:940-944, 1983
5) Jasper JR, Michel MC, Insel PA:Molecular mechanism of β-adrenargic receptor blockers with intrinsic symoathomimetic activity. FASEBJ 2:2891-2894, 1988
6) The xamoterol in severe heart failure study group:Xamoteroi on severe heart failure. Lancet 336:1-6, 1990
8) Bristow MR, Roden RL, Lowes BD et al:The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol 21 (suppl I):1-3-1-13, 1998
10) Townend JN, Littler WA:Cardiac vagal activity:a target for intervention in heart disaese. Lancet 345:937-938, 1995
11) Chidiac P, Hebert TB, Valiquette M et al:Inverse agonis-tactivity of β-adrenargic antagonist. Mol Pharmacol 45:490-499, 1993
12) Lowes BD, Chidiac P, Olsen S et al:Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β-adrenargic receptor blocking agents (abstr). Circulation 90:(suppl I) S543, 1994
P.59 掲載の参考文献
2) Wilkstrand J, Warnord L OIsson G et al:Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988
3) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
4) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157:2413-2446, 1997

Part 2 / β遮断薬の臓器別作用

P.66 掲載の参考文献
1) Eugene Braunwald:HEART DISEASE. In:Atextboole of cardiovascular medicine 5th edition, ed by Braunwald E, WB Saunders CO, Philadelphia, 1997, pp486-488, 610-613, 853-854, 1264, 1304-1308
2) Dzimiri N:Regulation of β-adrenoceptor signaling in cardiac fuction and discase. Pharmacol Rev 51:465-501, 1999
3) Steinberg S:The molecular basis for β-adrenergic receptor subtype actions in cardiomyocytes. Circ Res 85:1101-1111, 1999
4) Gauthier C, Tavernier G, Charpentier F et al:Functional β1-adrenoceptor in the human heart. J Clin Investing 98:556-562, 1996
5) Commumal C, Singh K, Sawyer DB et al:Opposing effects of β1-andβ2-adrenergic receptors on cardiac myocytc apoptosis. Circulation 100:2210-2212, 1999
7) Lubbe W, Todzuweit T, Opie H:Potential arrhyth-mogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload:Implications 66 for prophylactice effects of beta-blockers in myocardial infraction and proarrhythmic ef of phosphodiesterase inhibitors. J Am Coll Cardiol 19:1622-1633, 1992
8) Krishnan S, Levy N:Effects of coronary artery occlusion and reperfusion on the idioventricular rate in anesthetized dogs. J Am Coll Cardiol 23:1484, 1994
10) Hopson R, Maruns B:Hemodynamic and reflex sympathetic control of transmural activation and rate of ventricular tachycardia in ischemic and hypertrophic ventricular myocardium of the dog. Circulation 86:618, 1992
11) Ditchev V, Rubio-Perez A, Slinker K:Beta-adrencrgic blockade reduces niyocardial injury during experimental cardiopulmonary resuscilation. J Am Coll Cardiol 24:804, 1994
12) Bristow M:β-adrenergic receptor blockade in chronic heart failure. Circulation 101:558-569, 2000
13) Vanter S, Vanter D, Homcy C:β-adrenergic receplor signaling:An acute compensatory adjustment-inappropriate for the chronic stress of heart falure. Circ Res 86:502-506, 2000
14) Ungerer M, Bohm M, Elce JS et al:Ahered expression of β-adrenergic receptor kinase and, β1-adrenergic receptors in the failing, heart. Circulation 87:454-463, 1993
15) Ungerer M, Parruti G, Bohm M et al:Exprcssion or β-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res 74:206-213, 1994
16) Ungerer M, Keesebohm K, Kronsbein K et al:Activation of β-adrenergic receptor kinase during myocardial schemia. Circ Res 79:455-460, 1996
17) Dorn GW 2nd, Tepe NM, Lorenz JN et al:Low-and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc Natl Acad Sci Acad 196:6400-6405, 1999
18) Rockman HA, Chien KR, Choi DJ et al:Exprcssion of β-adrenergic reccptor kinase1 inhibitor prevents the development of myocardial failure in genetargeted mice. Proc Natl J Acad Sci USA 95:7000-7005, 1998
19) Akhter SA, Skaer CA, Kypson AP et al:Restoration ofβ Tadrenergic signaling in failing cardiac ventricular myocyte via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA 494:12100-12105, 1997
20) O'Connor CM, Ganis WA, Uretsky BF et al:Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart railure. Am Heart J 138:78-86, 1999
21) Iwasc M, Bishop SP, Uechi M et al:Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gs α overexpression. Circ Res 78:517-524, 1996
22) Asai K, Yang GP, Geng YJ et al:β-adrencrgic rcceptor blockade arrests nlyocyte damage and preserves cardiac function in the transgenic Gs α mouse. J Clin Invest 104:551-558, 1999
23) Milano CA, Allen LF, Rockman HA et al:Enhanced myocardial function in transgenic mice overexpressing the β2-adrenergic receptor. Science 264:582-586, 1994
24) Hausdorff WP, Caron MG, Lefkowitz RJ:Tuming off the signal:desensitization of β-adrenergic receptor function. FASEB J 4:2881-2889, 1990
P.73 掲載の参考文献
2) Melena J, Wood JP, Osborne NN:Betaxolol, a beta1-adrenoceptor antagoonist, has an affinity for L-type Ca2+channels. Eur J Pharmacol 378:317-322, 1999
3) Adachi T, Hori S, Miyazaki K et al:Rapid increase in plasma nitrite concertation following intravenoes administration nipradilol. Eur J Pharmacol 286:201-204, 1995
4) Hayashi T, Yamada K, Esaki T et al:The beta adrenoreceptor antagonist, nipradilol, preserves the enidothelial nitric oxide response in atheroscierotic vessels or rabbit. Lifee Sci 61:1379-1387, 1997
5) Cockcroft JR, Chowienczyk PJ, Brett SE et al:Nebivolol vasodilates human forearm vasculature:evidence for an L-arginine/NO-dependent mechanisni. J Pharmacol Exp Ther 274:1067-1071, 1995
6) Adler B, Gimbrone MA Jr, Schafer AI et al:Prostacyclin and beta-adrenergic catecholamines Inhibit arachidonate release and PGI2 synthesis by vascular endolhelium. Blood 58:514-517, 1981
8) Nishimiya T, Daniell HB, Webb JG:Chronic treatment with propranolol enhances the synthesis of prostaglandins E2 and I2 by thc aorta of s pontaneously hypertensive rats. J Pharmacol Exp Ther 253:207-213, 1990
10) Ohlstein EH, Arleth AJ, Storer B et al:Carvedilol inhibits endotheline-1 biosynthesis in cultured human coronary artery endothclial cells. J Mol Cell Cardiol 30:167-173, 1998
11) Saijonmaa O, Metsarinne K, Fyhrquist F:Carvedilol and its nietabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press 6:24-28, 1997
12) Krum H, Gu A, Wilshire-Clement M et al:Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 131:337-341, 1996
13) Krone W, Naegelce H, Behnke B et al:Opposite effects of insulin and catecholamines on LDL-receptor activity in human monocuclear leukocytes. Diabetes 37:1386-1391, 1988
16) Whittington-Coleman PJ, Carricr O Jr, Douglas BH:The efrects of propranolol on cholesterol-induced athcromatous lesions. Atherosclerosis 18:337-345, 1973
18) Linden T, Camejo G, Wiklund O et al:Effect of shortterm beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. J Clin Pharmacol 30 (suppl 2):S124-S13-1999
19) Yue TL, Wang X, Gu JL et al:Carvednol, a new vasodilating bcta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteirls by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 273:1442-1449, 1995
P.78 掲載の参考文献
2) 松本昌泰, 木村和文, 鎌田武信:脳底剖血管の神経薬理学的特性とその病理・病態的意義. 臨床科学:27:987-993, 1991
3) Fujishima M, Rcinmuth OM, Kogure K et al:The response of cerebral metabolism and flow to beta adrenergic blockade. Circtlation 37-38, VI-79, 1968
4) Aoyagi M, Deshmukh VD, Meycr JS et al:Effect of beta-adrenergic blockadc with propranolol on cerebral blood flow, autoregulation and CO, responsiveness. Stroke 7:291-295, 1976
7) Madsen PL, Vorstrup S, Schmidt JF et al:Effect of acute and prolonged treatment with propranolol on cerebral blood flow and cerebral oxygen metabolism in healthy volunteers. Eur J Clin Pharmacol 39:295-297, 1990
8) Olscn KS, Svendsen LB, Larsen FS et al:Effect of labetalolon cerebral blood flow, oxygen metabolism amd autoregulation in heathy humans. Br J Anaesth 75:51-54, 1995
9) Bunemann L, Jellsen KA, Riisager S et al:Cerebral blood flow and metabolism during hypertension induced with sodium nitroprusside and metoprolol. Eur J Anaesthesiol 8:197-201, 1991
10) Hares P, James IM, Grirtlith D:Thc effect or acebutolol on the cerebral circulation of man. Br J Clin Phramacol 4:373-375, 1977
11) Jacobson J, Schmidt JF, Waldemar G et al:The acute effect of dilevalol on cerebral blood now and oxygen consumption in normotensive humans. J Cardiovasc Pharmacol 15:574-578, 1990
12) Griffith DNW, James IM, Newbury PA et al:The effect of β-adrenergic receptor blocking drugs on cerebral blood flow. Br J Clin Pharmacol 7:491-494, 1979
15) Kuriyama Y, Sawada T, Omae T:Antihypertensive drugs and cerebral circulation. In:How should elderly hypertensive Patients be treated? ed by Omac T, Zanchctti A, Springer-Verlag, Tokyo, 1988, pp69-81
18) Skinner MH, Funerman A, Morrissette D et al:Atenolol compared with nifedipine:Effect on cognitive function and mood in elderly hypertensivc patients. Ann Int Med 116:615-623, 1992
19) 黒瀬等:アドレナリン受容体とドーパミン受容体. 蛋白質核酸酵素 42:120-130, 1997
20) Winder DG, Martin KC, Muzzio IA et al:ERK plays aregulatory role in induction or LTP by theta frequency stimulation and its modulation byβ-adrenergic receptors. Neuron 24:715-726, 1999
22) Heckbert SR, Longstreth WT, Psaty BM et al:The association of antihypertensive agents with MRI whitematter findings and with modified mini-mental state examination in older adults. J Am Geriatr Soc 45:1423-1433, 1997
24) Lysko PG, Lysko KA, Yue TL et al:Neuroprotective effects of carvedilol. a new antihypertensive agent. in cultured rat cerebellar neurons and in gerfil global brain ischemia. Stroke 23:1630-1636, 1992
25) Imura T, Shimohama S, Sato M et al:Differential expression or small heat shock proteins in reactive astrocytes after focal ischemia:possible role of β-adrenergic receptor. J Neurosurg Sci 19:9768-9779, 1999
27) 藤島正敏:β遮断薬の脳循環調節に及ぼす効果と脳卒中の発症予防. β遮断薬と高血圧-最新の知見からみた臨床応用-, 池田正男, 築川久一郎編, メディカルレビュー社, 1993, pp79-89
28) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihyperrensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
P.84 掲載の参考文献
1) Beaufils M:Alterations in renal hemodynamics during chronic and acute beta-blockade in humams. Am J Hypertens 2 (11part 2):233S-236S, 1989
2) Epstein M. Oster J:Beta-blockers and renal function:a reappraisal. J Clin Hypertens 1:85-89, 1985
3) Epstein M. Oster J, Hollenberg N:Beta-blockers and the kidney:implications for renal function and renin release. Physiologist 28:53-62, 1985
4) Epstein M. Oster J:Beta-blockers and the kidney. Mineral Electrolyte Metab 8:237-254, 1982
7) Struyker-Boudier H, Smits J:Antihypertensive action of beta-adrenoceptor blocking drugs. The role of intrarenal mechanisms. Am J Hypertens 2 (11 Part 2):237S-240S, 1989
9) Nakaoka H. Kitahara Y, Amano M et al:Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypetension 10:221-225, 1987
10) Pettersson K, Anderson J. Sjolander M et al:Atrial natriuretic peptide and the natriuresis due to acute beta blockadc in conscious hypertcnsive rats. Clin Exp Hypertens A 19:95-107, 1987
11) Struyker-Boudier H, Vervoort-Peters L, Rousch M et al:Beta-adrenoceptors in kidney tubules of spontaneously hypertensive and normotensive rats. Life Sci 38:137-145, 1986
12) Weber M, Drayer J:Rcnal errects of beta-eadrenoceptor blockade. Kidney Int 18:686-699, 1980
13) Cruz F, O'Neil W, Clifton G et al:Effects or labetalol and methyldopa on renal function. Clin Pharmacol Ther 30:57-63, 1981
14) Rasmussen S, Nielsen P:Blood pressure, body fluid volumes. and glomerular filtration rate during treatment with labetalol in essential hypertension. Br J Clin Pharmacol 12:249-353, 1981
16) Shiigai T:Erfects of long-term therapy with arotinolol on blood pressure and renal function in hypertensive patients with chronic renal failure. Clin Ther 15:330-336, 1993
17) Siewert-Dell A, Ljungman S. Hartford M et al:Efffect of 14 years of antihypertensive treatment on renal function and urinary albtimin excretion in prinlary hypertension. Am J Hypertens 9:841-849, 1996
P.89 掲載の参考文献
1) Prichard BN, Gillam PM:Use of propranolol (Inderal) in the treatment of hypertention. BJM 12:725-727, 1964
2) Lebrec D, Poynard T, Hillon P et at:Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis:a controlled trial. N Engl J Med 305:1371-1374, 1981
3) Ohnishi K, Nakayama T. Saito M et al:Effects of propronolol on portal hemodynamics in patients with choronic liver disease. Am J Gastroenterol 801132-135, 1985
5) Butzou GH. Remmecke J. Braucr A:Metoprolol in portal hypertension. A controlled study. Klin Wochescher 60:1311-1314, 1982
6) Yat PC, Cho CH:Effects of β-adrenocptor antagonists on portal vein hypertension and ethanol-induced gastric mucosal damage in rats. J Pharm Pharmacol 46:95-97, 1994
7) 関山達也, 古明池弘和, 大須賀勝ほか:肝硬変におけるαβブロッカー, Carvedilolの全身ならびに肝血行動態に対する影響. 臨床薬理28:203-204, 1997
8) Chellingsworth MC, Kendall MJ. Wright AD et al:The effect of verapamil, diltiazem nifedipine and proporanolol on matabolic control in hypertensives with noninsulin dependent, diabetes mellitus. J Hum Hypertens 3:35-39, 1989
11) Jacob S. Rett K. Henriken EJ:Antihypertensive therapy and insulin sensitivity:Do we have to redefine the role ofβ-blocking agents? Am J Hypertens 11:1258-1265, 1998

Part 3 / 血圧調節因子とβ遮断薬

P.96 掲載の参考文献
1) Nakaoka H. Kitahara Y, Amano M et al:Effect of β-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypeetension 10:221-225, 198796
2) Tonkin AL, Wing LM, Russell AE et al:Diltiazem and atenolol in essential hypertension:additivity of effects on blood pressure and cardiac conduction with combination theerapy. J Hypertens 8:1015-1019, 1990
3) Hollenbeck M. Plum J. Heering P et al:Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J Hypertens 9:819-824, 1991
4) Hama J. Nagata S, Takenaka T et al:Alrial natriuretic peptide and antihypertensive action due to β-blockade in essential hypertensive patients. Angiology 46:511-516, 1995
5) Fujimura M, Yasumura Y, Ishida Y et al:Improvement in letf ventricular function in response too carvedilol is accompanied by attenuation of neurofumoral activation in Patients with dilated cardiomyo Pathy. J Cardiac Failure 6:3-10, 2000
6) Richards AM, Doughty R. Nicholls MG et al:Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99:786-792, 1999
7) Yoshimoto T. Naruse M, Tanabe A et al:Potentiation of natriuretic peptide action by the β-adrenergic blocker carvedilol in hypertensive rats:a new antihypertensive mechanism. Endocrinology 139:81-88, 1998
8) Kishimoto I, Yoshimasa T, Suga S et al:Natriuretic peptide clearnce receptor is transcriptionally down-regulated by β2-adrenergic stimulation in vascular smooth muscle cells. J Biol Chem 7269:28300-28308, 1994
9) Luchner A. Burnett JC Jr. Jougasaki M et al:Augmentation of the cardiac natriuretic peptides by β-receptor antagonism:evidence from a population-based study. J Am Coll Cardiol 32:1839-1844, 1998
13) Seljeflot I, Arnesen H, Andersen P et al:Effect of doxazosin and atenolol n circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J Ca rdiovasc Pharmacol 34:584-588, 1999
15) Kakoki M, Hirata Y, Hayakawa H et al:Effects or vasodilatory β-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 33:467-471, 1999
16) Olbrich A. Salameh A. Roesen P et al:Different effects of the beta-adrenoceptor antagonist celiprolol and meloprolol on vascular structure and function in long-term type I diabetic rats. J Cardiovasc Pharmacol 33:193-203, 1999
17) Hayashi T. Yamada K. Esaki T et al:The β adrenoreceptor, nipradilol, preserves the endothehal nitric oxide response in atherosclerotic vessels of rabbit. Life Sciences 61:1379-1387, 1997
19) Thybo NK, Stephens N. Cooper A et al:Effect or antihypertensive treatment on small artcrics of patients with previously untreated essential hypertension. Hypertension 25:474-481, 1995
21) Senior R. Base S, Kinsey C et al:Carvedilol prevents remodeling in patients with left ecntricular dysfunction after acute myocardial infrarction. Am Herat J 137:646-652, 1999
22) Hansson L Lindholm LH. Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidily the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999

Part 4 / 高血圧

P.105 掲載の参考文献
1) The Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Prcssure, The National High Blood Pressure Education Program Coordinating Committee:The Sixth Report or the Joint National Committee on Prevention, Detectio, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
2) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17:151-183, 1999
3) Hansson L, Lindholm LH, Niskanen L et al for the Captopril Prevention Project (CAPPP) study group:Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevcntion Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
4) Hansson L Lindholm LH, Ekbom T et al for the STOP-Hypertension-2 study group:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
6) Ramsay LE, Williams B, Johnston GD et al for management of hypertension:report of the third working party of the British Hypertension Society. J Hum Hypertens 13:569-592, 1999
8) Feldman RD, Campbell N, Larochelle P et al for the Task Force for the Development of the 1999 Canadian Rccommendations for the Management of Hypertension:1999 Canadian recommendations for the management of hypertension. Can med Assoc J 161 (12supp):S1-S17, 1999
10) WHO Expert Committee:Hypertension control Report of a WHO Expert Committee. WHO Technical Report Series 862, World Health Organization. Geneva, 1996, pp 1-83
11) Messerli FH, Grossman E, Goldbourt U:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 279:1903-1907, 1998
12) Messerli FH, Grossman E:β-Blockers and diuretics:To use or not to use. Am J Hypertense 12 (12 Part 2):S157-S163, 1999
13) Messerli FH. Grossman E:Diuretics, bela-blockers, and gin and tonic. Eur Heart J 20:25-30, 1999
14) Staessen JA, Wang JG, Birkenhager WH et al:Treatment wilh beta-blockers for the primary prevention of thc cardiovascular complications of hypertension. Eur Heart J 20:11-25, 1999
16) Haim M, Shotan A. Boyko V et al for the Bezafibrate Infarction Prevention (BIP) Study Group:Effects of beta-bklocker therapy in patients with coronaryo artery discase in New York Heart Association Classes II and III.Am J Cardiol 81:1455-1460, 1998
17) Jonas M, Reicher-Reiss H Boyko V et al for The Bezafibrate Infarction Prevention (BIP) Study Group:Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery discase. Am J Cardiol 77:1273-1277, 1996
18) Rehnqvist N. Hjemdahl P, Billing E et al:Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 17:76-81, 1996
20) von Amim T for the TIBBS Investigators:Prognostic significance of transient ischemic episodes:Response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 28:20-24, 1996
21) Lau J, Antman EM, Jimenez-Silva J:Cumulative meta-analysis of therapeutic trials for myocardial infarction. J Engl J Med 327:248-254, 1992
23) Packer M, Bristow MR, Cohn JN et al for the Carvedilol Heart Failure Study Group:Thc effect on carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
24) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study-II (CIBIS-11):a randomised trial. Lancet 353:9-13, 1999
25) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
26) Kendall MJ, Lynch KP, Hjalmarson A et al:β-Blockcrs and sudden cardiac death. Ann Intern Med 123:358-367, 1999
28) Kennedy HL, Brooks MM, Barker AH et al for the CAST Investigators:Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 74:674-680, 1994
29) Kennedy HL:Beta-blocker prevention of proarrhyth-mia and proischemia:Clues from CAST, CAMIAT, and EMIAT. Am J Cardiol 80:1208-1211, 1997
30) Mangano DT, Layug EL, Wallace A et al for the Multicenter Study of Perioperative Ischemia Research Group:Effect of atenolol on morlality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 335:1713-1720, 1996
31) Toumilehto J, Wikstrand J, Olsson G et al:Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study. Hypertension 13:773-780, 1989
32) Weir MR, Moser M:Diuretics and β-blockers:Is there a risk for dyslipidemia? Am Heart J 139:174-184, 2000
33) Manttari M, Tenkanen L, Mannninen V et al:Antihypertensive therapy in dyslipidemic men. Effects on coronary heart diaease incidence and total mortality. Hypertension 25:47-52, 1995
35) The ALLHAT Officicers and Coordinators for the ALLHAT Collaborative Research Group:Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 283:1967-1975, 2000
P.111 掲載の参考文献
1) The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure:The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
2) Guidelines Subcommittee:1999 World Hethh Organization-International Society of Hypertension Guidelines for the Manegement of Hypertension. J Hypertens 17:151-183, 1999
3) MRC trial of treatment of mild hypertention:principal results. Medical Reserch Council Working Party. BMJ 291:97-104, 1985
5) SHEP Cooperative Research Group:Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255-3264, 1991
6) Dahlof B, Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
7) Dahlof B, Devereux R, de Faire U et al:The Losartan Intervention for Endpoint Reduction (LIFE) in hypertension study:rationale, design and methods. AM J, Hypertens 10:705-713, 1997
P.117 掲載の参考文献
1) Joint National Committee on detection, evaluation, and treatment of high blood pressure:the sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Intern Med 157:2413-2446, 1997
2) Guideline Subcommittee:1999 World Health Organization-International Society of Hypertension guideline for the management of hypertension. J. Hypertens 17:151-183, 1999
3) Lind L, Pollare T, Berne C et al:Long-term metabolic effects of antihypertensive drugs. Am Heart J 128:1177-1183, 1994
5) Barron HV, Viskin S, Lundstrom RJ et al:β-blocker dosages and mortality after myocardial infarction. Data from a large health maintenance organizatio. Arch Intern Med 158:449-453, 1998
7) Soriano JB, Hoes AW, Meems L et al:Increased survival with β-blockers:importance of ancillary properties. Prog Cardiovasc Dis 39:445-456, 1997
9) Basu S, Senior R, Raval U et al:Beneficial effects of intravenous and oral Carvedilol treatment in acute nyocardial infarction. A placebo-controlled, randomized trial. Circulation 96:183-191, 1997
10) Flack JM, Neaton J, Grimm R et al:Blood pressure and mortahty among men with prior myocardial infarction. Circulation 92:2437-2445, 1995
11) Messerli FH, Grossman B, Goldbourt U et al:Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903-1907, 1998
12) Waagstein F, Hjalmarson A, Varnauskas E et al:Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036, 1975
14) CIBIS Investigators and Committees:A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765-1773, 1994
16) Packer M, Colucci WS, Sackner-Bernstein JD et al:Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation 94:2793-2799, 1996
18) Australia/New Zealand Heart Failure Research Collaboiative Group:Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failurc due to ischaemic heart disease. Lancet 349:375-380, 1997
19) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
20) CIBIS-II Investigators and Committees:The Cardiac Insufficiency Bisoprolol Study II (CIBIS II):a randomised trial. Lancet 353:9-13, 1999
21) Doughty RN, Rodgers A, Sharpe N et al:Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 18:560-565, 1997
22) Kukin ML, Kalman J, Charney RH et al:Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, xercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651, 1999
23) 藤島正敏:脳血管障害の血圧管理(急性期~慢性). 日内会誌80:553-558, 1991
24) Simonson DC:Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 11:821-827, 1988
P.128 掲載の参考文献
1) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, The National High Blood Presure Coordnaiting Committee:the sixth report of the joint national committee on prevention, detection, evaluation, treatment of high blood Pressure.Arch Intern Med 157:2413-2446, 1997
2) 1999 World Health Organization-International Society of Hypertellsioll Guidelines for the Management of Hypertension. J Hypertens 17:151-183.1999
3) Bauer JH, Rcalns GP:Antiyhpertensive drugs. In:Brenner & Rector's the kidney. 5th ed, ed by brenner BM, Saunder WB, Pennsylvania, 1996,pp.2331-2381.
4) Dupont AG, Vanderniepen P, Bossuyt AM et al:Nadololin essential hypertension:effect on ambulatury blood pressure, renal haemodynamics and cardiac function. Br J Clin Pharmacol 20:93-99, 1985
5) Bauer JH, Reams GP, Lau A:A comparison of xolol and nadolol on renal function in essential hypertension. Am J Kidney Dis 10:109-112, 1987
6) Ibsell H. Sederberg-Oslcn P:Changes in glomerular filtration rate durng long-term treatment with propranolol in patients with arterial hypertension. Clin Sci 44:129-134, 1973
7) Wilkerson R. Stevens IM, Pickering M et al:A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension. Br J Clin Pharmacol 1O:51-59, 1980
8) Dc Leeuw PW, Birkenhager WA:Renal response to propranolol treatment in hypertensive hunans. Hypertension 4:125-131, 1982
9) Malini PL, Strocchi E, Negroni S et al:Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol 13 (suppl):S123-S126, 1982
10) Pastemack A. Porsti P, Poyhonen L:Effect of pindolol and propranolol on renal function of Patients with hypertension. Br J Clin Pharmacol 13 (supp)::S241-S244. 1982
11) Van den Meiracker AH, Man in't Veld AJ, Boomsma Fet al:Hemodyriamic and β-adrencrgic receptor adaptations during long-term β-adrenoceptor blockade. Circulation 80:903-914, 1989
12) Baba T, Murabayashi S, Tomiyama T et al:Comparison of the renal effects of dilevalol and carteolol in patients with mild moderate essential hypertension. Eur J Clin Pharmacol 38:305-307, 1990.
13) Belini G, Bttilana G, Carretta R et al:Antihypertensive effects and kidney function in hypertensivc patients treated with atenolol and oxprenolol. Clin Exp Curr Ther Res 32:99-105, 1982
16) Tavemer D, MacKay IG, Craig K et al:Thc effects or selective β-adrenoceptor antagonists and partial antagonist activity on renal function during exercise in normal subjects and those with ni oderate renal impairmem. Br J Clin Pharmacol 32:387-391, 1991
17) Thompson FD, Joekes AM, Hussein MM:Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br J Clin Pharmacol 8 (supp):S129-S133. 1978
18) Valvo E. Previato G, Tessitore N et al:Effects of the long-term administration of labetalol on blood pressure, hemodynamics and renal function in essential and renal hypertension. Clin Exp Curr Ther Res 39:634-643, 1981
19) Williams JG, De Vossk, Craswell PW:Labetalol in the treatment of hypertensive patients. Med J Aust 1:225-228, 1978
20) Stornell M, Valvo EV, Scappellato L:Comparative effects of enalapril, atenolol, and chroltharidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 58:52-57, 1991
22) Bjorck S. Mulec H, Johnsen SA et al:Renal effect or enalapril in diabetic nephropahty. BMI 304:339-343, 1992
24) Bakris GL, Wilson DM, Bumett JC:The renal, forearm and humoral responses to standing in the presence and absence of propranolol. Circulation 74:1061-1065, 1986
25) 北本清, 長澤俊彦, 猿田享男ほか:高血圧を合併する慢性腎疾患に対するnipradilolの臨床的有用性-降圧効果, 腎機能および尿蛋への影響. 腎と透析7:115-125. 1999
26) 金子裕美, 中岡稔, 藤巻正慶ほか:腎実質性高血圧症および透析患者におけるβ遮断薬カルベジロールの体内動態. 臨床薬理23:127-128, 1992
27) 武田忠直, 石井當男, 猿田享男ほか:腎性高血圧に対するCarvedilol (DQ-2446) の長期投与時の有効性ならびに安全性の検討. 診断と治療82:506-522, 1994
28) Shiigai T:Effects of long-term therapy with arotinolol on blood pressure and renal function in hypertensive patienls with chronic renal failure. Clinical Therapeutics 15:330-337, 1993
29) Man in't Veld AJ, Schalekamp MA:Effects of 10 different β-adrenoceptor antagonists on hemodynamics, plasma renin activity, plasma norepinephirne in hypertension:the key role of vascular resistance changes in relation to partial antagonist activity. J Cardiovasc Pharmacol 5 (suppl 1):S30-S45. 1983
30) 吉永馨, 荒川規矩男, 池田正男ほか:褐色細胞腫21例におけるLabctalolの効果. ホルモンと臨床 29:515-522, 1981
31) 大石誠一, 佐々木雅人, 森岡由紀ほか, α・β:受容体遮断薬 (YM-09538) による褐色細胞腫の治療-ラベタロールおよびブナゾシンとの比較. 臨床と研究64:2274-2250. 1987
32) 吉永馨, 三浦幸雄, 鹿野秦邦ほか:褐色細胞腫に対する塩酸アモスラロール (YM-09538)の治療効果:医学と薬学20:1526-1539. 1987
33) 佐々木雅人, 大石誠・, 梅田照久ほか:術前, 新α・β受容体遮断薬(YM-09538)により血圧調節を行った副腎外褐色細胞腫の1例. ホルモンと臨床35:187-190, 1987
36) Struthers AD, Reid JL, Whitesmith R et al:The effect of cardioselective and non-selectivc β-adrenoceptor blockade on thc hypokalemic and cardiovascular responses to adrenomedullary hormones in man. Clin 71 Sci 65:143-147, 1983
38) Ramsay L, Williams B, Johnston G et al:Guidelines for management of hypertension:report of the third working party of the British Hypertension Society. J Hum Hypertense 13:569-592, 1999
39) 角田一男:妊娠中の高血圧. 現代医療27:143-152, 1995
P.134 掲載の参考文献
1) National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents:update on the 1987 task force report on high blood pressure in children and adolescents:A working group report from the National High Blood Pressure Education Program. Pediatrics 98:649-658, 1996
2) カプランNM:一次性高血圧:自然歴, 特別な集団, 評価臨床高血圧, カプランNM編, 医学書院MYW, 東京, 1995, pp113-146
4) 村田和子, 齊藤郁夫:血圧のトラッキング現象,日本臨床(増刊号)高血圧(下):397-401, 2000
5) Zinner SH. Martin LF, Sacks F et al:A longitudinal study of blood pressure in childhood. Am J Epidemiol 100:437-442. 1975
6) Babkin SW, Mathewson FAL. Tate RB:Relationship of blood pressure in 20-39-year-old men to subsequent blood pressure and incidence of hypertension over a 30-year observation period. Circulation 65:291-299, 1982
8) 齊藤郁夫:肥満と高圧.慶應保険研究16:6-10, 1998
9) 広瀬寛, 辻岡三南子, 河邊博史ほか:若年軽度肥満者の血圧におよぼす体重コントロールの影響-3年間の追跡調査. 慶應保健研究17:35-38, 1999
10) 和井内英樹, 辻岡三南子, 河邊博史ほか:成人男子における高血圧の発症予測因子. 慶應保健研究 17:45-49, 1999
11) Hirose H, Saito L Tsujioka M et al:The obese gene product, leptin:possible role in obesity-related hypertension in adolescents. J Hypertens 16:2007-2012, 1998
14) Post WS, Larson MG, Levy D:Hemodynamic predictors of incident hypertension. The Framingham Heart study. Hypertension 24:585-590, 1994
15) 齊藤郁夫:青少年の高血圧. 今日の高血圧治療 2 (4):18-19, 1998
17) 三浦幸雄:血圧検査, 学生の健康白書・1995-基本編-, 学生の健康白書作成に関する特別委員会編, 国立大学等保健管理施設協議会, 東京, 1997, pp74-88
18) 内川聖:小児期からの成人病の予防と診療の実際-高血圧.治療 77:3108-3112, 1995
20) Julius S, Mejia A, Joncs K et al:"White coat" versus "sustained" borderline hypertension in Tecumseh, Michigan. Hypertension 16:617-623, 1990
21) 齊藤郁夫:若年者における白衣高血圧の頻度ならびに血液脂質の検討. 慶應保健研究15:19-23, 1997
22) Julius S. Jamerson K:Sympathetic, insulin resistance and coronary risk in hypertension:the "chicken-and-egg" question. J Hypertens 12:495-502, 1994
23) Rocchini AP, Kcy J. Bondie D et al:The effect of weight loss on the sens itivity of blood pressure to sodium in obese adolescents. N Engl J Med 321:580-585, 1989
26) Ramsay LE, Williams B, Johnston GD et al:Guidehnes for management of hypertension:report of the Third Working Party of the British Hypertension-Society. J Hum Hypertens 13:569-592, 1999
27) Owens PE, Lyons S, O'Brien E:Can heart rate predict blood pressure response to anti-hypertensive drug therapy? J Hum Hypertens 12:229-233, 1998
19}Saito L Murata K, Tsujioka M et al:Long-term changcs in clinic blood pressure in patients with white-coat hypertcnsion. Blood Press Monitor 3:97-100, 1998
P.140 掲載の参考文献
3) 蔵本築, 池田正男, 荒川規矩男ほか:老年者および壮年者本態性高血圧に対するβ遮断薬の有用性-bunitolol二重盲検試験の検討. 日老医誌 21:20-26, 1984
4) Coope J. Warrender TS:Randomizcd trial of treatmem of hypertension in elderly patients in primary care. Bri Med Clin Res 293:1145-1151, 1986
5) Dahlof B. Lindholm LH, Hansson L et al:Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension. STOP-Hypertens ion. Lancet 338:1281-1285, 1991
6) Ekbom T, Dahlof B, Hansson L et al:Antihypertensive efficacy side effects of three beta-blockers and a diuretic in elderly hypertensives:A report frrom the STOP-Hypertension study. J Hypertens 10:1525-1530, 1992
7) MRC Working Party:Medical Research Council trial of treatment of hypertension in older adults:principal results. BMI 340:405-415. 1992
8) Hansson L, Lindholm LH. Ekbom T et al:Randomise trial of old and new antihypertensive drugs in elderly patienls:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756. 1999
9) Held PH, Yusuf S:Effets of β-blockers and calcium channel blockers in acute Inyocardial infarction. Eur Heart J 14 (suppl F):S18-S25. 1993
10) Sackner-Bernstein JD. Mancini DM:Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 274:1462-1467, 1995
11) Waagstein F, Bristow MR, Swedberg K et al for thc Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993
12) CIBIS Investigators and Commiuces:A randomized trial of β-blockade in heart failure:Thc Cardiac Insufficiency Bisoprolol Study (CIBIS) , Circarlation 90:1765-1773. 1994
14) Bristow MR, Gilbert EM. Abraham WT et al:Carvedilol produces dosc-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996
15) Joint National Committee on Prevcntion. Detection, Evaluation, and Treatment of High Blood Pressure:The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) . Arch Intern Med 157:2413-2446, 1997
16) 日和田邦夫, 萩原俊男, 松本正幸ほか:老年者高血圧治療ガイドライン-1999年改訂版-厚生省長寿科学総合研究「老年者高血圧の長期予後に関する研究」班. 日老医誌36:576-603. 1999
P.147 掲載の参考文献
1) Millar-Craig MW, Mann S, BalaSubramanian V et al:The effect of oxprenolol on ambulatory intra-arterial blood pressure in essential hypertension. Eur J Clin Pharmacol 24:713-721. 1983
3) 藤木嘉人, 栃久保修, 石井當男ほか:血圧・脈拍数の日内変動に及ぼすBopindololの影響-本態性高血圧症外来患者での検討-. Thera Peutic Research 10:2533-2542, 1989
5) 小竹親夫, 小屋祐司, 池田宗一郎ほか:本態性高血圧に対するacebutololおよびmetoprololの効果. 特に日内変動に対す効果. 呼吸と循環40:885-890, 1992
6) Neutel J M., Schnaper S, Cheung DG et al:Antihypertensive effects of β-blockers administrred once daily:24-hour measuremnlts. Am Heart J 120:166-171, 1990
7) Parati G, Pomidossi G, Casadei R et al:Evaluation of the antihypcrtensive efffect of celiprolol by ambulatory blood pressure monitoring. Am J Cardiol 61 (suppl C):S27-S33. 1988
9) Mann S, Millar-Craig MW, BalaSubramanian V et al:Propranolol LA and ambulatory blood pressure. Br J Clin Pharmacol 10:443-447, 1980
10) Mancia G, Ferrari A, Pomidossi G et al:Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertcnsive treatment by once-a-day nadolol. Am Heart J 108:1078-1083. 1984
11) Hornung RS, Gould BA, Keiso H et al:A study of nadolol on determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing. Br J Clin Pharmacol 14:83-88, 1982
12) 林博史, 松波龍幸, 平井真理ほか:24時間血圧変動から見た. 本態性高血圧に対するNipradilol (ハイパジール) の効果. Thera Peutic Reaserch 12:3545-3554, 1991
14) Millar-Craig MW, Kenny D, Mann S et at:Effect of once-daily atenolol on ambulatory blood pressure. BMJ 1:237-238, 1979
16) 劉会中, 田村潔, 三好甫ほか:塩酸ベタキソロールの使用経験-多類多群β遮断薬とのクロスオーバー比較試験-第1報:1209-1221. 1998随時 日内変動値からみた長期投与・の有効性と安全性. 臨床と研究75::1209-1221. 1998
17) Al-Khawaja IM, Caruana MP, Prince FH et al:Once and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording. Am J Cardiol 58 (suppl E):S17-S20. 1986
18) BalaSubramanian V, mann S, Millar-Craig M W et al:Effect of Labctalol on continuous ambulatory blood pressure. Br J Clin Pharmacol 8 (suppl 2):S119-S123, 1979
19) White WB, Lund-Johanson P, Omvik P:Twentyfour-hour blood pressure load as a surrogate and point in assessing antihypertensive therapy. J Hypertens 11 (suppl 4):S75-S80. 1993
20) 塩見利明, 小林正, 矢野弓子・ほか:本態性高血圧症外来患者における血圧の日内変動・日内リズムに対するarotinolol hydrochlorideの影響-非観血的形態型自動血圧計による1日1回投与と1日2回分割投与の比較-. 循環器科26:345-353, 1989
21) Palatini P, Spreti G, Cordone L et al:Twenty four-hour continuous in direct blood pressure monitoring during treatment with slow release metoprolol and atenolol. Acta Therapeutica 12:23-32, 1986

Part 5 / 合併症を伴った高血圧とβ遮断薬

P.155 掲載の参考文献
1) Wikstralld J, Warnold L Tuomilehto J et al:Metoprolol versus thiazide diuretics hl hypertension:morbidity results from the MAPHY study. Hypertension 17:579-588, 1991
2) Dahlof B, Lindholm LH. Hansson L et al:Morbidity and mortality in the Swedish Trial on Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991
3) Fletcher A, Beevers DG, Bupitt C et al:Beta adrenoceptor blockade is associated with incrcased survival on male but not female hypertensive patients:a report from the DHSS Care Computing Project (DHCCP). J Hym Hypertens 2:219-227, 1988
4) Medical Research Council Working Party:MRC trial of treatment of mild hypertension:principal resulls.:BMJ 291:97-104, 1985
5) The IPPPSH Collaborative Group:Cardiovascular risk and risk factors in a ramdomized trial of treatment based on the beta-blocker oxprenolol:the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 3:379-392, 1985
6) Snow PJD et al:Effect of propranolin myocardial infarction. Lancet ii:551-553, 1965
7) ISIS-1 (First Internatioal Study of Infarct Survival) Collaborative Group:Randomized trial of intravenous atenolol among 16027 cases of suspected acutc myocardial infraction:ISIS-1. Lancet 335:57-66, 1986
8) The MIAMI (Metoprolol in Acute Myocardial Infraction) Trial Rescarch Group:Metoprolol in acute myocardial infarction. AM J Cardiol 56:1G-57G, 1985
9) The TIMI (Thrombolysis in Myocardial Infarction) study Group:Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 320:618-627. 1989
10) Hjalmarson A, Elmfeldt D, Herlitz J et al:Effect on mortality of metoprolol in acute myocardial infarction:adouble-blind randomised trial. Lancet ii:823-827. 1981
11) The Beta-blocker Heart Anack Study Group:Beta-Blocker Heart Attack Trial. JAMA 246:2073-2074, 1981
13) Soumerai SB, McLaughlin TJ, Spiegelman D et al:Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 277:115-121, 1997
14) Michael J, Henrietta R. Solmon B et al:Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease.Am J Cardiol 77:1273-1277, 1996
15) Kul C, Sidney G, Robert B et al:Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73:503-510, 1986
16) Stephen SG, Robert JM, Robert AV:Effect of beta-blockade on mortality among high risk and low-risk patients after myocardial infarction. N Engl J Med 4339:489-497. 1998
17) Milton P. Michael RB, Jay NC et al the US Carvedilol Heart Failure Stydy Group:Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med 334:1349-1355, 1996
18) Packer M:Pathophysiological mechanism under-lying the effects of β-adrenergic in agonists and antagonists on funcional capacity and survival inchronic heart failure. Circulation 82 (suppl 1):1-77-1-88, 1990
19) Sato H, Hori M, Ozaki H et at:Exercise-induced upward shift of diastolic left ventricular pressure volume relation in patients with dilated cardiomyopathy:effects of β-adrenoreceptor blockade. Circulation 88:2215-2223, 1993
20) Morikawa M, Sato H, Koretsune Y et al:Sustained eft ventricular diastolic dysfunction arter exercise in patients with dilated cardiomyopathy:a form of diastolic stunning. Circulation 92 (supp 1):S540, 1995
21) CIBIS Investigators and Committees:Arandomized trial of β-blockade in heart failure:thc Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765-1773, 1994
22) Salim Y, Richard P. John L et al:Beta btockade during and after myocardial infarction. An overview of the randomized trials. Prog Cardiovasc, Dis 5:335-371, 1985
23) Paul H, Sven VE, Nina R et al:Prognosis of patients with stable angina pectoris on antianginal drug therapy. Am J Cardiol 77:6D-15D. 1996
24) Hal VB, Sami V, Joe VS et al:β-blocker dosages and mortality after myocardial infarction. Arch Intern Med 158:449-453. 1998
P.160 掲載の参考文献
2) Gottdiener JS:Hypcrtensive heart disease in blacks. Cardiovasc Clin 21:133-134. 1991
3) Why HJF. Richardson PJ:Effect of carvedilol on left ventricular function and mass in hypertension. J Cardiovasc Pharmacol 19 (Suppl 1):S50-S54, 1992
4) Neaton JD, Grimm RH Jr, Prineas RJ et al:Treatment of mild hypertension study. Final results. JAMA 270:713-724, 1993
6) Schobel HP. Langenfeld MRW. Gatzka CD et al:Treatment and post-treatment effects of alpha-versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J 132:1004-1009, 1996
7) Gottdiener JS, Reda DJ. Massie BM et al:Effect of single drug therapy on reduction on left ventricular mass in mild to moderate hypertension. Circulation 95:2007-2014. 1997
8) Dahlof B. Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. AM J Hypertens 5:95-110, 1992
9) Cruickshank JM, Lewis J. Moore V et al:Reversebility of left ventricular hyperlrophy by differing types or antihypertensive therapy. J Hum Hypertens 6:85-90, 1992
10) Schmieder RE. Martus P. Klingbeil A:Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275:1507-1513, 1996
P.167 掲載の参考文献
2) Tanaka H. Obata H, Haneda T et al:Effects of regression of left ventricular hypertrophy following atenolol or bunazosin therapy on ischemic cardiac function and myocardial metabolism in spontaneously hypertensive rats. Jpn Circ J 55:1233-1245, 1991
3) Singh BN, Courtney KR:Classification of antiarrhy-thmic mechanisms of drug action:experimental and clinical considerations. In:Cardiac Electro Physiology:From Cell to Bedside, ed by Zipes DP, Jalife J, WB Saunders Company, Philadelphia, 1990, pp882-897
4) Miyazaki T. Zipes DP:Pericardial prostaglandin biosynthesis prevents the increased incidence of reperfusion-induced ventricular fibrillation produced by efferent sympathetic stimulation in dogs. Circulation 82:1008-1019, 1990
7) Muller JE, Ludmer PL. Willich SN et al:Circadian variation of in the frequency of sudden cardiac death. Circulation 75:131-138, 1987
8) Beta Blocker Heart Attack Trial Research Group:A randomized trial of propranolol on patients with acute myocardial infarction. L Mortality results. JAMA 247:1707-1714, 1982
10) Kleiger RE, Miller JP, Bigger JT Jr et al:Decreased heart rate variability and its association with increased mortality after acute myocardial infacrtion. Am J Cardiol 59:256-262, 1987
11) LaRovere MT, Specchia C, Mortara A et al:Barore-flex sensitivity. clinical correlates and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation 78:816-824. 1988
12) Goel BG, Han J:Atrial ectopic activity associated with sinus bradycardia. Circulation 42:853-858, 1970
13) Rostango C. Taddei T. Daladini B et al:The Onset or symptomatic atrial fibrillation and Paroxysmal supraventricular tachycarctia is characterized by different circadian rhythms. Am J Cardiol 71:453-455, 1993
14) Yamashila T. Murakawa Y. Hayami N et al:Relation between aging and circadian varation of Paroxysmal atrial fibrillation. Am J Cardiol 82:1364-1367. 1998
15) 心拍変動の臨床応用-生理的意義, 病態評価, 予後予測-, 林博史編, 医学書院, 東京, 1999
16) Saul JP. Arai Y. Berger RD et al:Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol 61:1292-1299, 1988
17) 斉藤寛和, 大阪元久, 佐々部典子ほか:発作性頻脈性不整脈発症時の自立神経活動. 心電図13:181-188. 1993
18) Huikuri HV. Valkama JO, JuhaniAiraksinen KE et al:Frequency domain measures of heart rate variability before the onset of nonsustained and sustained ventricular tachycardia in Patients with coronary artery disease. Circulation 87:1220-1228, 1993
19) Vaughall Williams EM:Classitlcation of antiarrhyth-mic drugs. In:Symposium on Cardiac Arrhythmias, Astra, Sweden. 1970. pp 449-472
22) Reader EA. Verrier RL. Lown B:Intrinsic sympathomimctic activity and the effects of beta-adrenergic blocking drugs on vulnerability to ventricular fibrillation. JACC 1:1442-1449. 1983
24) Shanks RG:The properties of beta-adrenoceptor antagonists. Postgrad Med J 52 (suppl):S14-S20, 1976
25) Fenster PE, Reynolds D. Horwitz LD et al:Atenolol for ventricular ectopy:a dose-response study. Clin Pliarmacol Thier 41:118-123. 1987
28) 宮崎利久, 新村健, 井上詠:電気生理学検査による発作性上室性頻拍への薬効評価と有効薬剤の慢性効果. 心臓 24:1233-1241, 1992
30) Brugada P, Brugada J:Right bundle branch block. persistent ST segment elevation and sudden cardiac death. A distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol 20:1391-1396. 1992
31) 加藤和三, 早川弘一, 新博次ほか:超短時間作用型β遮断薬:塩酸ランジオロール (ONO-1101)の発作性心房細動・粗動, 発作性上室性頻拍に対する臨床評価-3. 用量比較による多施設共同オープン比較試験(用量設定試験)臨床医薬13:4873-4901, 1997
32) Reynolds RD. Gorczynski RJ, Quon CY:Pharmacology and pharmacokinetics of esmolol. J Clin. Pharmacol 26 (suppl A):A3-A14. 1986
33) Prichard BNC:Beta-adrenergic reccptor blockade in hypertension, Past, present and future. Br J Clin Pharmacol 5:379-399, 1978
34) Hirsowitz G, Pordrid PJ, Lawpert S et al:The role of beta blocking agent as adjunct therapy to membrane stabilizing agents in malignant ventricular arrhythmia. Am Heart J 111:852-860, 1986
36) Pfisterer M, Kiowski W, Brunnrr H et al:Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 87:309-311, 1993
37) Mason JW for the ESVEM investigators:Acomparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl Med 329:445-451, 1993
39) 循環器疾患の発症リズム・悪化のリズム-生体リズムを考慮した時間診断と時間治療, 林博史編, Progress in Medicine 18 (2):195-342. 1998
P.173 掲載の参考文献
1) Levy D, Garrison RJ, Savage DD et al:Prognostic implications of echocardiographically determines left ventrucular mass in the Framingham Heart study. N Engl J Med 322:1561-1566, 1990.
2) Verdecchia P, Schilliaci G, Borgioni C et al:Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
3) The SOLVD Investigators:effects of enalapril on mortality and the development of heart failure in asymotomatic patients with reduced left ventricular ejection fraction. N Engl J Med 327:685-691, 1992
4) The CONSENSUS Trail Study Group:Effect os enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian Enapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435, 1987
5) Kleber FX, Niemoller L, Doering W et al:Impact of Converting enzymes inhibition on progression of chronic heart failure:result of the Munich Mild Heart Failure Trial. Br HEart J 67:289-296, 1992
7) Waagstein F. Hjalmarson A, Varnauskas E et al:Effect of chronic β-adrenergic receptor blocade in congestive cardiomyopathy. Br Heart J 37:1022-136, 1975
8) Swedberg K, Hjalmarson A, Waagstein F et al:prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet i:1374-1376, 1979
9) ANZ Heart Failure Research Cooperative Group:Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 319:375-380, 1997
10) Brislow MR. Gilbert EM, Abraham WT et al:Carvedilol produces dose-related improvrments in left ventricular functiond survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996
11) Packer M. Brislow MR, Cohn JN et al:The effects carvedilol on morbidility and mortality in patients with chronic heart failure. N Engl J Med 331:13491355, 1996
13) CIBIS-II Investigators and Committees:The Cardiac insufficiency bisoprolol study II (CIBIS-II) a randomised trial.Lancet 353:9-13, 1999
14) The International Steering Committee on Behalf of the MERIT-HF Study Group:Rationale, Design and Organixation of the Metroprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 80 (suppl J):S54-S58, 1997
15) XISHF Study Group:Xamoterol in severe heart failure. Lancet 336:1-6. 1990
P.178 掲載の参考文献
1) Cortes P, Riser BL, Zhao X et al:Glomerular volume expansion and mesangial cell mechanical strain-mediators of glomerular pressure injury-. Kidney Int 45 (suppl):S11-S16, 1994
2) Anderson S, Brenner BM:Progressive renal disease:a disorder of adaptation. Q J Med 70:185-189. 1989
3) Arendshorst WJ, Navar LG:Renal circulation and glomerular hemodynamics. In:Textbook of Diseases of the kidney, 4th ed, ed by RW Schrier, CW Gottschalk, Little Brown, Boston, 1998, pp 65-117
4) de Jong PE, Anderson S, de Zeeuw D:Glomerular preload and afterload reduction as a tool to lower urinary protein leakage:will such treatments also help to improve renal function outcome? J Am Soc Nephrol 3:1333-1341, 1993
6) 木村玄次郎:腎と高血圧-病態生理からのアプローチ-, 東京医学社, 東京, 1998
7) Praga M, Hernandez E, Montoyo C et al:Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. AM J Kidney Dis 20:240-248. 1992
8) Gansevoort RT, de Zeeuw D, de Jong PE:Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in non-diabetic renal disease. Am J Kidney Dis 22:202-206, 1993
10) The GISEN Group:Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
12) Hannedouche T, Landais P, Goldfarb B et al:randomised controlled trial of analapril and beta blockers in non-diabetic chronic rcnal failure. BMJ 309:833-837, 1994
13) Swedish Lisinopril Study Group:Lisinopril combined with atenolol in the treatment of hypertension. J Cardiovasc Phamacol 18:457-461, 1991
14) Soininen K, Gerlin-Piira L, Suihkonen J et al:A study of the etfects of lisinopril when used in addition to atenolol. J Humz Hypertens 6:321-324, 1992
15) 北本清, 長澤俊彦, 猿川亨男ほか:高血圧を合併する慢性腎疾患に対するnipradilolの臨床的有用性-降圧効果, 腎機能および尿蛋白への影響-. 腎と透析473:115-125, 1999
16) Nakamoto H, Nemoto H, sugahara S et at:Nifedipine and arotinolol in combination for accelerated malignant hypertension:result of one year follow-up Hypertension Res 22:75-80, 1999
17) Maruhn D, Paar D, Bock KD:Lysosomal and brush border membrane enzymes in urine of patients with renal artery stenosis and with essential hypertension. Clin Biochem 12:228-220, 1979
19) 河野雅和, 安成憲一, 村川浩一ほか:本態性高血圧患者の尿中N-アセチル-β-D-グルコサミニダーゼならびにアラニンアミノペプチダーゼ排泄に及ぼすカルベジロール長期投与の影響. 血圧3:640-644, 1996
20) Hall W, Kusek J, Kirk K et al:Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate:the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 29:720-726, 199
22) Peterson JC, Adler S, Burkart JM et al:Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 123:754-762, 1995
P.184 掲載の参考文献
1) Fujishima M, Ibayashi S, Fujii K et al:Physiology of cerebral blood flow and theory or its measurement. In:Quantitative Cerebral Blood Flow Measurements Using Stable Xenon/CT, ed by Tomonaga M, Tanaka A, Yonas H, Furuta Publ Co, New York, 1995, pp11-25
2) Fujishima M, Ibayashl S, Fujii K et al:Cerebral blood flow in hypertension. Hypertens Res 18:111-117, 1995
5) Hypertension-Stroke Cooperative Study Group:Effect of antihypertensive treatment on stroke recurrence. JAMA 229:409-418, 1974
7) The INDANA Project Collaborators:Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. Stroke 28:2557-2562, 1997
9) Arakawa S, Saku Y, Ibayashi S et al:Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke 29:1806-1809, 1998
10) 藤島正敏, 佐渡島省三, 石束隆男:降圧薬と脳循環. 脳卒中 11:1-10, 1989
11) Globus M, Keren A, Eldad M et al:The effect of chronic propranolol therapy on regional cerebral blood flow in hypertensive patients. Stroke 14:964 967, 1983
12) Griffith DNW, James IM, Newburv PA et al:The effect of β-adrenergic receptor blocking drugs on cerebral blood flow. Br J Clin Pharmacol 7:491-494, 1979
13) Medical Research Council Working Party:MRC trial of treatment of mild hypertension. Principal results. BMJ 291:97-104, 1985
14) MRC Working Party:Medical Research Council trial of treatment of hypertension in older adults:principal results. BMJ 304:405-412, 1992
15) Kinnander G, Viitanen M, Asplund K:Beta-adrenergic blockade after stroke. A preliminary closed cohort study. Stroke 18:240-243, 1987
17) Dutch TIA Trial Study Group:Trial of secondary prevention with atenolol after transient ischemic attack on nondisabling ischemic stroke. Stroke 24:543-548, 1993
18) McMahon S, Rodgers A, Neal B et al:Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension 29:537-538, 1997
21) PROGRESS Management Committee:Blood pressure lowering for the secondary prevention of stroke;design and rationale for PROGRESS. J Hypertens 14 (suppl 2):S41-S46, 1996
P.188 掲載の参考文献
1) Bengtsson C, Blohme G, Lapidus L et al:Do antihypertensive drugs precipitate diabetes? BMJ 289:1495-1497, 1984
2) 片山茂裕,盛川俊介:糖尿病患者に対する循環器薬の使い方. Cardiologist 4:367-371, 1999
3) Berne C, Pollare T, Lithell H:Effect of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14:39-47, 1991
4) Kosegawa I, Inaba M, Morita T et al:Effects of the vasodilatory β-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens 20:751-761, 1998
5) Jacob S, Rett K, Wicklmayr M et al:Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity:the carvedilol-metoprolol study. J Hypertens 14:489-494, 1996
7) Lithell H, Anderson P-E:Metabolic effects of carvedilol in hypertensive patients. Eur JPharmacol 52:13-17, 1997
9) Shorr RI, Ray W, Daugherty JR et al:Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278:40-43, 1997
10) Kjekshus J, Gilpin E, Cali G et al:Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 11:43-50, 1990
P.194 掲載の参考文献
1) Working Group on Management or Patients with Hypertension and High Blood Cholesterol:National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med 114:224-237, 1991
3) Sacks FM, Dzau VJ:Adrenergic effects on plasma lipoprotein metabolism. Am J Med 80 (suppl 2A):S71-S81, 1986
4) Leren P, Helgeland A, Hjermann I et al:The Oslo study:CHD risk factors, socioeconomic influences, and intervention. Am Heart J 106:1200-1206, 1983
5) Kasiske BL, Ma JZ, Kalil RS et al:Effect of antihypertensive therapy on serum lipids. Ann Intern Med 122:133-141, 1995
6) Fogari R, Zoppi A, Corradi L et al:β-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 33:534-539, 1999
7) Goto Y, Tamachi H, Fusegawa Y et al:Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc Pharmacol 18 (suppl 4):S45-S50, 1991
8) Hauf-Zachariou U, Widmann L, Zulsdorf B et al:A double-blind comparison of the effects of carvedilol and captopril on serum lipid cancentrations in patients with mild to moderate essential hypertension and dyslipidemia. Eur J Clin Pharmacol 45:95-100, 1993
9) Jacob S. Rett K, Henriksen EJ:Antihypertensive therapy and insulin sensitivity:Do we have to redefine the role of β-blocking agents? Am J Hypertens 11:1258-1265, 1998
10) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
11) Wikstrand J, Warnold I, Tuomilehto J et al:Metoprolol versus thiazide diuretics in hypertension. Mobidity results from the MAPHY study. Hypertension 17:579-588, 1991
12) The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, The National High Blood Pressure Education Program Coordinating Committee:The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
13) Guideline Subcommitee of the WHO-ISH Mild Hypertension Liaison Committee:1999 World Health Organization-Internationl Society of Hypertension Guidelines for the Management or Hypertension. J Hypertens 17:151-183, 1999
14) UK Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvasular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-713, 1998
15) Chobanian AV, Brecher P, Chan C:Effects of propranolol on atherogenesis in the cholestcrol-fed rabbit. Circ Res 56:755-762, 1985
17) Camejo G, Hurt E, Thubrikar M et al:Modification of low density lipoprotein association with the arterial intima. A possible environment for the antiatherogenic action of β-blockers. Circulation 84 (suppl VI):S17-S22, 1991
18) Feuerstein GZ, Ruffolo RR Jr:Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 17 (suppl B):S24-S29, 1996
19) Donetti E, Soma MR, Barberi L et al:Dual effects of the antioxidant agents probucol and carvedilol on profilerative and fatty lesions in hypercholesterolemic rabbits. Atherosclerosis 141:45-41, 1998
20) Radack K, Deck C:β-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151:1769-1776, 1991

Part 6 / 虚血性心疾患治療薬としてのβ遮断薬

P.202 掲載の参考文献
2) Hjalmarson A, Elmfedt D, Herlity Z et al:Effect on mortality of metoprolol in acute myocardial infarction:a double-blind randomised trial. Lancet ii:823-827, 1981
4) Beta-Blocker Heart Attack Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247:1707-1714, 1982
7) The ISIS-1 collaborative group:Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infartion. ISIS-1. Lancet ii:57-66, 1986
8) Roberts R, Rogers WJ, Mueller HS et al:Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction:results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation 83:422-437, 1991
9) Pfisterer M, Cox JL, the Granger CB et al:Atenololse and clinical outcomes after thronibolysis for acute myocardial infarction:1he GUSTO-1 experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.J Am Cardiol 32:634-640,1998
10) Rankin JM, Spinelli JJ, Carere RG et al:Improved clinical outcome after widespread use olcoronary artery stenting in Canada. N Engl Med 3411:1957-1965,1999
11) Grines CL, Cox DA, Storlc GW et al:Coronary angioplasty with or without stent implantation forcute myocardial in farction. Stent Primaly Angioplasty in Myocardial Intfarction Study Group.Eng J Med 341:1949-1956.1999
12) Topol EJ, Byzowa TV, Plow EF:Plalelet GPIIb/IIIa blockers.Lancet 353:227-231.1999
13) Basu S, Senior R, Raval U et al:Beneficial effects of intraverlous and oral carvedilol treament in acute myocardial infarction:aplacebo-controlled, randomized trial. Circulation 96:183-191.1997
16) Ishikawa K, Kanamasa K, Hayashi T et al:Drugr treatment for secondary prevention of myocardial nfarction. J Cardiol 35:397-408.2000
P.209 掲載の参考文献
1) Haffner SM, Lehto S Ronnemaa T et al:Mortality from coronary heart disease in subject with type 2 diabetes and in nondiabetic subject with and without prior myocardial infarction. N Engl J Med 339:229-234,1998
2) Free N, Cleland J, Young P et al:β-bockade after myocardial nnfarction:systematic review and meta regression analysis, BMJ 318:1730-1737, 1999
3) β-Blocker Heart Attack Trial Research Group:A randomized trial of [rp[ranolol in patients with acute myorcardial infarction. JAMA 247:1707-1714, 1982
5) Krumholz HM, Radford MJ, Weng Y et al:Early β-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med 131:648-654, 1999
6) Yasue H. Ogawa H, Tanaka H et al on behalf of the Japanese Antplatelets Myocardial Infarction Study (JAMIS) Investigators:Effects of aspirin and trapidil on cardiovascular events after acute myocardial after acute. Am J Cardiol 83:1308-1313, 1999
8) Yasue H. Omole S, Takizawa A et al:Coronarv artery spasm in ischemic heart disease and its pathogeneis. A review. Circ Res 52 (suppl I):S147-S152, 1983
9) Gonttlieb SS, McCarter RJ, Vogel RA:Effect of belta-blockade on mortalily among hing-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489-497, 1998
10) Basu S. Senior R, Raval U et al:Beneficial effects of intavenous and oral carvedilol treatmennt in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 96:183-191, 1997
P.215 掲載の参考文献
1) Heberden W:Commentaries on the history and cure of discases. In:Classics of Cardiology, ed by Willius FA, Keys TE, Henry Schuman, Dover Publ, New York I, 1941, p221
2) ISFC/WHO Task Force on standardization on clinical nomenclature:nomenlature and criteriafor diagnosis of ischemic heart disease. Circulation 59:607-609, 1979
4) 半田俊之介, 和井内由充子, 谷正人ほか:安定労作狭心症患者の運動耐容能規定因子-冠動脈病変と冠血流予備能. 呼と循 39:917-923, 1991
5) Okumura K, Yasue H, Matusyama K et al:Sensitivity and specificity of intracoronary injectin of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol 12:883-888, 1988
7) 半田俊之介, 朝倉靖:異型狭心症の疫学・現代医療 25:1373, 1993
8) Fuster V, Badimon L Badimon JJ et al:The patho-genesis or cornary artery disease and the acute coronary syndorme. N Engl J Med 326:242-250, 310-318, 1992
9) 半田俊之介, 青木直人:Syndrome X患者に長期的薬物治療は必要か. Modern Physician 14 1101:1205-1209, 1994
10) Sigwart U. Grbic M. Pavot M et al:In:Silent Mrocardial Ischemia, ed by Rutishauser W. Roskamm H. Berlin, Springer-Verlag, 1984
12) Cohn PF:Silent myocardial ischemia:Present status. Mod Concepts in Cardiovasc Dis 56:1. 1987
15) Guidelines on management of stable effort angina pectoris Recommendations of the Task Force of the Europe; in Sociely of Cardiology. Eur Heart J 18 131:394-413, 1997
16) 半田俊之介:狭心症治療の概要:狭心症とβ遮断薬, 臨床薬理と臨床応用, 海老原昭夫, 中村芳郎編, 中外医学社 1989, pp68-113
17) Committee on Management of Patients with Chronic Stable Angina:ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina:Executive summary and recommendations Circulation 99:2829-2848, 1999
21) Dunselman P, Liem AH. Verdel G et al:Addition of felodipinc to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adcquate beta-blockade, results of the felodipine ER and metoprolol CR inangina (FEMINA) study. Eurr Heart J 18:1755-1764. 199
22) Armstrong PW:Stable ischemic syndromes. In:Textbook of Cardiovascular Medicine ed by Topol EJ, Lippincon-Raven Publ, Philadelphia, p333, 1998
23) 半田俊之介, 赤石誠:抗狭心症薬-突然死をいかに予防するか. 現代医療25:3605-3611,1993
24) Gottlieb SS, McCarter RJ, Vogel RA:Effect o beta-blockade on mortality among high-risk and low-risk patients affer myocardial infarction. N Engl J Med 339:489-497, 1998
25) 半田俊之介, 椎名豊:狭心症患者における心不全の治療, 循環器NOW14狭心症, 南江堂, 東京, 1996, pp200-204
27) Avezum A. Tsuyuki RT. Pogue J et al:Beta-blocker therapy for congestive heart failure:asystematic overview and critical appraisal of the pubhshed trials. Cann J Cardiol 14:1045-1053. 1998
28) ANZ Hcart Failure Research Collaborative Group:Randomized. placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 34:375-380. 1997
30) Fragasso G, Chierchia SL, Pizzetti G et al:Impaired left ventricular filling dynamics in patients with angina and angiographically normal corollary arteries:effect of beta-adrenergic blockade. Heart 77:32-39, 1997
32) Gottlieb SO. Weistfeldt ML, Ouyang P et al:Effect of the addition of Propranolol to therpy with nifedipine for unstabel angina:a randomized double-blind placebo-controlled trial. Circulation. 73:331-337. 1986
33) Yusufs, Wittes J. Friedman L:Overview of result of randomized clinical trials in heart disease. II. unstable agina, heart failure, primary prevention with aspirin and risk factor reduction. JAMA 260:2259-2263. 1988
34) Rizik D. Timmis GC. Grines CL et al:Immediate use of beta-blockers, but not calcium blockers . improves prognosis in unstable angina(abstr). Circulation 84 (suppl II):S345. 1991
35) Lubsen J, Tijsen JGP, Kerkkamp HJJ et al:Early trtatment of unstable angina in the coronary care unit:A randomiezed. double blind. placebo controlled comparison of recurrent ischaemia in patients treated with niftdipine or metoprolol or both:Report of thr Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 56:400-413, 1986
36) Brunner M, Faber TS, Greve B et al:Usefulness of carvedilol in unstable angina pectoris. Am J Cardiol 85:1173-1178. 2000
37) Jonas M. Reicher-Reis:H, Boyko V et al:Usefulness of beta-blocker therapy in Patients with non-insulin dependent diabetes mellitus and coroonary artery disease. Am J Cardiol 77:1273-1277. 1996
38) 半田俊之介, 吉川勉:β遮断薬. Medical Practice 10:587-592. 1993
P.221 掲載の参考文献
1) Cohn PF:Silent myocardial ischemia:classification. prevalence. and prognosis. Am J Med 79 (3A):2-6. 1985
2) Davies RE Goldberg AD, Forman S et al:Asymptomatic Cardiac Ischemia Pilot (ACIP) study two year follow-up:outcomes of patients randomized to initial strategies of medical therapy versus revascularizatioll. Circulation 95:2037-2043, 1997
4) Deanfield JE, Detry JM, Lichtlen PR et al:Amlodipine reduces, transient myocardial ischemia in Patients wilh coronary artery disease:double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 24:1460-1467, 1994
5) Tzivoni D, Kadr H, Braat S et al:Efficacy of mibe-fradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia:results of amulticenter, placebo-controlled trial. Circulation 96:2557-2564. 1997
6) von Arnim T:Medical treatment to reduce total ischemic burden:total ischemic burden bisoprolol study (TIBBS) . a multiceter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 25:231-238, 1995
8) Dauselman P, Liem AH. Verdel G et al:Addition of felodipine to metoprolol vs replacement of metroprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN) . Eur Heart J 18:1755-1764. 1997
10) Fox KM. Mulcahy D. Findly I et al:The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the excrcise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 17:96-103. 1996

Part 7 / 不整脈治療薬としてのβ遮断薬

P.228 掲載の参考文献
5) ISIS-1 Collaborative Group:Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction:ISIS-1 Lancet 5:57. 1986
6) Andresen A, Ehlers HC, Wiedemann M et al:Beta blockers:evidence versus wishful thinking Am J Cardiol 83 (5B):64D-67D, 1999
9) Duff H, Roden D, Bronson L et al:Electrophysiologic actions high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol 2:1134-1140, 1983
12) Frisham WH:Beta-adrenergic blockers. Med Clin North Am 72:37-81, 1988
13) Bramah NS. Jonnalagedda SM:Beta-Blockers and Calcium Channel Blockers as Antiarrhythmic Drugs. In:Cardiac Electrophysiology, From Cell to Bedside. ed by Zipes DP, WB Saunders. Philadelphia, PA. 1999, pp903-920
15) Huycke EC, Lai WT, Nguygn NX et al:Role of intravenous isoproterenol in the electrophysiologic induction or atrial ventricular nodal reentrant tachycardia in patients with dual atrial ventricular nodal pathways. Am J Cardiol 64:1131, 1989
16) Kuppersmith J:Cellular mechanism of antiarrhythmic action or beta blockers. In:Beta-Blockers and Cardiac Arrhythmias, ed by Deedwania PC, Marcel Dekkar, New York, 1992, pp 1-33
17) William MM, Douglas PZ:Atrioventricular Reentry and Vaiants:Mechanisms, Clinical Features, and Management. In:Cardiac Electrophysiology From Cellto Bedside, ed by Zipes DP. WB Saunders, Philadelphia, PA, 1999, pp 488-504
18) Raymond Y, George JK, Eric P:The Wolff-Parkinson-White Syndrome and Related Variants. In:Cardiac Etectrophysiology From Cell to Bedside, ed by Zipes DP, WB Saundcrs. Philadelphia, PA, 1999.pp 845-861
19) The Cardiac Arrhythmia Suppression Trial II Investigators:Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Eng J Med 327:227-233, 1992
20) Doval HC, Nul DR, Gracelli HO et al for Grupo de Es tudio de la Sobrevida en la Insuficiencia Cardica en Argenitina (GESICA):Randomized trial of low-dose amiodarone in severe congestive heart failure:Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina(GESICA). Lancet 344:493-498, 1994
22) Singh SN, Fletcher RD. Fisher SG et al for the Survival Trial of Antiarrhythmic Therapy in Conjestive Heart Failure(CHF-STAT):Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia(CHF-STAT). N Eng J Med 333:77-82. 1995
23) Jeinek MV, Lown B:Exercise stress testing for exposure of cardiac arrhythmias. Prog Cardiovasc Dis 16:497-522, 1974
26) Yasue H, Horia Y, Nakamura N et al:Induction or coronary artery spasm by acetylcholine in patients with variant angina:possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74:955-963, 1986
27) Buxtoll AE, Marchlinski FE. Doherty JU et al:Repetetive monomorphic ventricular achycardia:clinical and electrophysiologic characteristics in patiens with and patients without organic heartdisease. Am J Cardiol 54:997-1002. 1984
28) Gilmore RF Jr, Hegger JJ. Prystowsky EM:Cellular Electrophysiological abnormalities of diseased human ventricular myocardium. Am J Cardiol 51:137, 1983
29) Zipes DP:Genesis of cardiac arrhythmias:electrophysiologic considerations. In:Heart Disease:A Textbook of Cardiovascular Medicine. ed by E Braunwald, WB Saunders, Philadelphia PA, 1997, pp548-592
31) Reiffel JA. Hahn E. Hartz VL for the ESVEM Investigators:Sotatol for ventricular tachyarrhythmias:Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. Am J Cardiol 79:1048-1053, 1997
32) The CASCADE Investigators:Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 72:280-287. 1993
34) Lichstein E, Hager WD, Gregory JJ:Relationship between beta adrenergic blocker use, various correlates of left ventricular function, and the chance of developing congestive heart failure. J Am Coll Cardiol 16:1327-1332, 1990
35) Heidenreich PA, Lee TT, Massie BM:Effect of beta bbckade on mortality in patients with heart failure:A meta-analysis of randomized clinica trials. J Am Coll Cardiol 39:27-34, 1997
38) Fraser GR. Froggatt P, James TN:Congenital deafness associated with electrocardiographic abnormalities, fainting attacks and sudden death. Q J Med 33:362. 1964
39) Garza LA, Vick RL. Nora JJ et al:Heritable Q-T prolongation without deafness. Circulation 41:39, 1970
41) Arthur JM, Wojciech Z, W Jackson H:Effectiveness and Limitatiolls of β-Blocker Therapy in Congenital Long-QT syndrome. Circ 101:616-623. 2000
43) Brodsky MA, Allen BJ. Bessen M et al:Beta-blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction. Am Heart J 115:799-808, 1988
45) Szabo BM, Crijns HJ. Weisfeld AC et al:Predictors of mortality in patiens with sustained ventricular tachycardias and ventricular fibrillation and depressed left ventricular function:importance of beta-blockade. Am Heart J 130:281-286. 1995

Part 8 / 心不全治療薬としてのβ遮断薬

P.237 掲載の参考文献
1) Waagsteill Y, Hjalmarson A, Varnauskas E et al:Effect or chronic beta-adrcnergic receptor blockade in congestive cardiomyopathy. Br Heart J 7:1022-1036,1975
2) BEST (Beta-Blocker Evaluation of Survival Trial) study group:the beta-blocker evaluation survival trial (abstr) . Circulation 100 (18), 1999
3) Waagsteill F, Bristow MR, Swedberg K et al for the Meloprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446,1993
4) CIBIS investigators and committees:Arandomized trial of β-blockade in heart failure; the cardiac insufficiency bisoprolol study (CIBIS). Circulation 90:1765-1773, 1994
5) CIBIS-H investigators and committees:The cardiac insufficiency bisopeolol study II (CIBIS-II):a randomized trial. Lancet 353:9-13,1999
6) Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007,1999
7) Packer M, Bristow MR, Cohn JN et al for the US Carvedilol Heart Failure Study Group:The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355. 1996
9) Australia/New Zealand Heart Failure Research Collaborative:Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart discase. Lancet 349:375-380, 1997

Part 9 / その他の疾患治療薬としてのβ遮断薬

P.244 掲載の参考文献
2) Richardson P, McKenna W, Bristow M et al:Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93:841-842, 1996
3) Harrison DC, Braunwald E, Glick G et al:Effects of beta adrenergic blockade on the circulation, with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 29:84-98, 1964
5) Frank MJ. Abdulla AM, Watkins LO et al:Long-term medical management of hypertrophic cardiomyopathy:Usefulness of propranolol. Eur Heart J 4 (suppl F):S155-S164, 1983
6) Gilligan DM, Chan WL, Stewart R et al:Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 68:766-772, 1991
7) Louie EK, Edwards LC:Hypertrophic cardiomyopathy. Cardiovasc Dis 36:275-308, 1994
8) Fananapazir L, Cannon RO III. Tripodi D et al:Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β-adrenergic blocker therapy. Circulation 85:2149-2161, 1992
9) Hamada T, Ohga M, Matsumoto M et al:Usefulness of isoproterenol infusion to determine the indication of dual-chamber pacing in patients with provokable left ventricular outflow obstruction with drug-refractory symptoms. J Arrhythmia 15:335-340, 1999
10) Zareba W, Moss AJ, Schwartz PJ et al:Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 339.:960-965, 1998
11) Schwartz PJ:Idiopathic long QT syndrome:Progress and questions. Am Heart J 109:399-411, 1985
16) Curran ME, Splawski I, Timothy KW et al:A molecular basis for cardiac arrhythmia:HERG mutations cause long QT syndrome. Cel 80:795-803, 1995
17) Sanguinetti MC, Jiang C, Curran ME et al:A mechanistic link between an inherited and an acquired cardiac arrhythmia:HERG encodes the I??, potassium channel. Cell 81:299-307, 1995
20) Shimizu W, Antzelevitch C:Sodium channel block with mexiletine is effective in reducing dispersion or repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 96:2038-2047, 1997
21) Shimizu W, Antzelevitch C:Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome:Effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 98:2314-2322, 1998
22) Moss AJ:Clinical management of patients with the long QT syndrome:Drugs, devices and gene-specific therapy. PACE 20:2058-2060, 1997
23) Yamaguchi B, Yoshida T, Ohga M et al:Acase of congenital long QT syndrome treated as epilepsy. Kokyu to Junkan, 2000 (in press)
24) Eldar M, Griffin JC, VanHare GF et al:Combined use of beta-adrenergic agents and long-term cardiacpacing for patients with the long QT syndrome. J Am Coll Cardiol 20:830-837, 1992
25) Dorostkar PC, Eldar M, Belhassen B et al:Longterm follow-up of patients with long-QT syndrome treated with β-blockers and continuous pacing. Circulation 100:2431-2436, 1999
26) Goldenberg IF, Almquist A, Dunbar DN et al:Prevention of neurally-mediated syncope by selective beta-1 adrenoceptor blockade (abstr). Circulation 76 (suppl IV):IV-133, 1987
27) Muller G, Deal BJ, Strasburger JF et al:Usefulness of metoprolol for unexplained syncope and positiveresponse to tilt testing in young persons. Am J Cardiol 71:592-595, 1993
28) 水牧功一, 藤木明, 林秀樹ほか:循環器領域における・失神Head-up tilt試験にて長時間の心停止を伴う失神発作が誘発されたneurally mediated syncopeの2症例. Jpn Circ J 59(suppl ii):S863-S868, 1995
29) Kukushima S, Kobayashi Y, Nakagawa H et al:Triggering mechanism for neurally mediated syncope induced by head-up tilt test. role of catecholamines and response to propranolo. J Am Coll Cardiol 33:350-357, 1999
30) Asso A, Milstein S, Dunnigan A et al:Prognostic significance of parenteral metoprolol during head-up tilt testing (abstr). Circulation 84 (suppl ii):S409. 1991
32) Kapoor WN, Smith M, Miller NL:Upright tilt resting in evaluating syncope:acomprehensive literature review. AM J Med 97:78-88, 1994
33) Lurie KG, Dutton J. Mangat R et al:Pindolol is effective in patients with vasovagal syncope (abstr). Pacing Clin Electrophysiol 15:592. 1992
34) 笠木寛治, 御前隆, 小西淳二:I:甲状腺疾患の診断:I:甲状腺疾患の画像診断. 日内会誌86:1126-1130, 1997
35) Wocber KA:Thyrotoxicosis and the heart. N Engl J Med 327:94-98, 1992
36) Olshausen K Bischoff S. Kahaly G et al:Cardiac arrhythmias and heart rate in hyperthyroidism. AM J Cardiol 63:930-933, 1989
38) Price HL, Cooperman LH, Warden JC:Control of the splanchnic circulation in man. Role of beta-adrenergic receptors. Circ Res 21:333-340, 1967
39) Lebrec D:β-blockers and portal hypertension hemodynamic effects and prevention or recurrent gastrointestinal bleeding. Hepatology 37:556-560, 1990
40) Imai F:Drug therapy for the treatment of portal hypertension. Nippon Geka Gakkai Zasshi 97:89-97, 1996
43) Mally J, Stone TW:Efficacy of an adenos ine antagonist, theophylline. in essential tremor:comparison with placebo and propranolol. J Neurol Sci 132:129-132, 1995
46) Koguchi Y, Nakajima M. Kawahara M et al:Clinical subtypes of essential tremor and their electrophysiological and pharmacological differences. Clin Neurol 35:132-136, 1995
51) Janezewski P, Bouulanger C, Iqbal A et al:EIldothelium-dcpendent effects of carteolol.J Pharmacol Exp Ther 247:590-595, 1988
52) 玉置泰裕, 富川憲, 新家真ほか:カルテオロール点眼の家兎視神経乳頭の末梢循環に及ぼす影響-レーザースペック眼底末梢循環解析機による検討-. 日眼会誌 99:895-goo, 1995
53) Messmer C. Flammer J, Stupfig D:Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 112:678-681, 1991
54) Fama E Santaniaria S:Comparison of the ocular effects of three beta-blockers; timolol, carteolol, and betaxolol. Ann Ophthalmol 28:317-320, 1996

Part 10 / 併用治療におけるβ遮断薬

P.252 掲載の参考文献
1) Guidelines Subcommittee:1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension.J Hypertens 17:151-183, 1999
3) Frishman WH, Bryzinski BS. Coulson LR et al:A multifactorial trial design to assess combination therapy in hypertension.Treatment with bisoprolol and hydrochlorothiazide.Arch Intern Med 154:1461-1468, 1994
5) Ncutel JM:Metabolic manifestations of low-dose diuretics.Am J Med 101 (Suppl 3A):S71-S82, 1996
6) The Joint National Committee:The sixth report of the Joint National Committee on prevention, detection, evalution, and treatment of high blood pressure.Arch Intern Med 157:2413-2446, 1997
7) Ronnevik PK, Silke B, Ostergaard O:Felodipine in addition to beta-adrenergic blockade for angina pectoris. a muhicentre, randomized, placebocontrolled trial. Eur Heart J 16:1535-1541, 1995
8) Ruilope LM, Coca A:The role of combination therapy in the treatment of hypertension. Blood Press 7 (suppl I):22-26, 1998
11) Ishimitsu T, Yagi S. Sugishita Y et al:Long-term effects of doxazosin, an alpha 1-blocker, on serum lipids in hypertensive patients. Hypertens Res 19:43-49, 1996
13) Hauf-Zachariou U, Widmann L, Zulsdorf B et al:A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 45:95-100, 1993
15) Hansson L:Beta-blockers with ACE inhibitors-a logical combination? J Hum Hypertens 3:97-100, 1989
16) Swedish Lisinopril Study Group:Lisinopril combined with atenolol in thc trcatment or hypertension.J Cardiovasc Pharmacol 18:457-461.1991
P.261 掲載の参考文献
1) 甲谷哲郎:無症候性心筋虚血. 心臓病診療プラクティス第8巻, 文光堂, 東京, 1996, p17-21
2) Deedwania PC, Nelson JR:Pathophysiology of silcnt myocardial ischemia during daily life:hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circutation 82 11296-1304,1990
4) Thadani U, Goli VG, Olson EG et al:Beta blockers in transient ischemic syndronie. In:Medical Therapy of Ischemic Heart Disease, ed by Abrams J, Little Brown, Boston, 1992, pp 259-285
5) 加藤和三, 飯沼宏之, 稲垣義明ほか:血管拡張作用を有するβ遮断薬carvedilol (DQ-2466) の狭心症に対する臨床効果. 臨床と研究 67:618-631,1990
6) 加藤和三, 岸田浩, 飯沼宏之ほか:トレッドミル運動負荷試験を用いたCarvedilol(DQ-2466) の狭心症に対する臨床評価. 臨床と研究67:632-648.1990
7) Gibbon RJ, Chatterjee K, Daley J et al:ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina;A report or the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee On Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 33:2092-2197, 1999
8) Wang TJ. Stafford RS:National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med 25:1901-1906, 1998
P.266 掲載の参考文献
1) Morganroth J:Antiarrhythmic cffects of beta-adrenergic blocking agents in benign or potentially lethal ventricular arrhythmias, Am J Cardiol 60:10D-14D.1987
2) 杉本恒明:診療基準:不整脈診療基準に関する調査研究. Jpn Circ J 55 (suppl II):267-288.1991
3) 抗不整脈薬併用療法研究会:抗不整脈薬併用療法ガイドライン. 心電図13:218-226,1993
4) 高田重男, 島倉泰淳, 五十嵐厚ほか:不整脈と筋交感神経活動. 心電図13:155-163,1993
6) Morttdy F, Kou WH. Kadish AH et al:Antagonism of quinidine's electrophysiologic effects by epinephrine in patients with ventricular tachycardia. J Am Coll Cardiol 12:388-394.1988
8) 高橋玉奈, 桜田春水, 岡崎英隆ほか:心室頻拍に対しamiodaroneとβ遮断薬の併用が有効と考えられた陳旧性心筋梗塞の1例. Prog Med 15:2127-2135, 1995
9) 水牧功一, 藤木明, 林秀樹ほか:拡張型心筋症に合併した難治性心室頻拍に対するアミオダロン, カルベジロールの併用療法. Prog Med 18:573-576, 1998
12) 鈴木与志和, 石坂恭一, 小林明ほか:ホルター心電図法による抗不整脈薬の効果判定に関する研究. 日内会誌 71:1-10, 1982
13) Bigger JT Jr:The interaction of mexiletine with other cardiovascular drug. Am Heart J 107:1079-1085, 1984
15) Hirsowitz G. Podrid PJ:The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia. Am Heart J 111:852-860, 1986
16) Deedwania PC, Olukotun AY, Kupersmith J et al:Beta blockers in combintition with class I antiarrhythmic agents. Am J Cardiol 60:21D-26D, 1987
17) Kobayashi A, Yamazaki N, Kobayashi T et al:Efficacy of combination therapy with mexiletine and a low dose of propanolol for premature ventricular arrhythmias. Jpn Circ J 54:1486-96.1990
19) 新博次, 井上博, 大城雅也:不整脈治療薬としてのCarteololの位置づけに関する共同研究. 臨床と研究67:277-287,1990
24) Friehling TD, Lipshutz H, Marinchak RA et al:Effectiveness or propranolol added to a type I antiarrhythmic agent for sustairied ventricular tachycardia secondary to coronary artery disease. Am J Cardiol 65:1328-1333,1990
25) 椎井雅博, 井上博, 山下武志:Flecainideとβ遮断薬の併用が有効であったFallot四徴症根治術後の持続性心室頻拍の1例. 心電図11:772-778,1991
26) 臼田和生, 高橋由起, 中林智之ほか:発作性心房細動に対するIc群薬とβ遮断薬の併用効果. Prog Med 17:2821-2827, 1997
27) Coumel P:Autonomic arrhythmogenic factors in paroxysmal atrial fibrillation. In:A trial Fibrillation. Mechanisms and Therapeutic Strategies. ed by Olsson SB, Alicssic MA, Campbell RWF, Futura Publishing Co, Armonk,1994, pp171-185
28) Lcwis GP, Holtzman JL:Interaction of flecainide with digoxin and propranolol Am J Cardiol 5:3:52B-57B, 1984

Part 11 / β遮断薬とQOL

P.276 掲載の参考文献
1) Dimsdale JE:Reflexion or the impact of antihypertensive medications on mood, sedat on. and neuropsychologic functioning. Arch Intern Med 152:35-39, 1992
3) Thiessen BQ, wallace SM, Blackbarn JL et al:Increased prescribing of antidepressants subsequent to β-blocker therapy. Arch Intern Med 150:2286-2290, 1990
6) Zachariah PK, Brobyn R, Kann J et al:Comparison of quality of life on nitrendipine and propranolol. J Cardiovasc Pharmacol 12 (suppl 4):S29-S35, 1989
7) Fletcher AE, Chester PC, Hawkins CMA et al:The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 3:125-130, 1989
8) Steiner SS, Friedhoff AJ.Wilson BL et al:Antihypertensive therapy and quality of life:a comparison of atenolol, captopril. enalapril and propranolol J Hum Hypertens 4:217-225, 1990
9) Weir MR. Josselson J, Ekelund LG et al:Nicardipine as antihypertensive mono therapy:Positive effects on quality or life. J Hum Hypertens 5:205-213.1991
11) Herrick AL. Waller PC, Berkin KE et al:Comparison of enalapril and atenolol in mild to moderate hypertension. Am J Med 86:421-426,1989
12) Blumental JA, Ekelun L-G. Emery CF:Quality of life among hypertensive patients with a diuretic background who are taking atenol and enalapril. Clin Pharmacol Ther 48:447-454,1990
14) Palmer AJ, Fletcher AE, Rudge PJ et al:Qulity of life in hypertensives treated with atenolol or captopril:a double-blind crossover trial. J Hypertens 10:1409-1416,1992
15) Jern S, Hansson L, Schersten B et al:Swedish isradipine study in hypertension:evaluation of quality of life, safety, and efficacy. SWISH group. J Cardiovasc Pharmacol 18 (suppl 3):S7-S8,1991
20) Dahlof C, Almoqvist G, Dimenas E et al:No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR. Ann Clin Res 20 (suppl 48):S42-S50.1988
21) Dahlof C. Hedner T, Thulin T et al:Effects of diltiazem and metoprolol on blood pressure, adverse symptoms and general well-being. The Swedish diltiazem-metoprolol multi-centre study group. Eur J Clin Pharmacol 40:453-460,1991
22) The treatment of mild hypertension research group:The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapics. Arch Intern Med 151:1413-1423, 1991
27) Hjemdahl P, Wiklund IK:Quality of life on antihypertensive drug therapy:scientific endpoint or marketing exercise? J Hypertens 10:1437-1446, 1992
29) Wiklund I, Waagstein F, Swedberg K et al:Quality of life on treatment with metoprolol in dilated cardioniyopathy:Results from the MDC trial. Cardiovasc Drugs Ther 10:361-368, 1996
30) Coulucci WS, Packer M, Bristow MR et al for the US Carvedilol Heart Failure Study Group:Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94:2800-2806, 1996
31) Cohn JN, Fowler MB, Bristow MR et al for the US Carvedilol Heart Failure Study Group:Safety and efficacy of carvedilol in sevcre heart failure. J Card Fail 3:173-179, 1997
32) Fowler MB:β-blockers in heart failure. Do they improve the quality as well as the quantity of life? Eur Heart J 19 (suppl P):S17-S25.1998
33) Rehnqvist N Hjemdahl P. Billing E et al:Effects or metoprolol vs verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS).Eur Heart J 17:76-81, 1996
25}Cleophas TJM, van der Mey N, van der Meulen J et al:Quality of life berore and during antihypertensive treatment:a comparative study of celiprolol and atenolol. Int J Clin Pharmacol Ther 34:312-317, 1996
P.282 掲載の参考文献
1) Meisel SR, Kutz I, Dayan KI et al:Effect of Iraqi missile war on incidence of acute myocardial intfarction and Sudden death in Israel civilians. Lancet 338:660-661.1991
4) Matsuo T, Suzuki S. Kodama K et al:Hemostatic activation and cardiac events after thc 1995 Hanshin-Awaji Earthquake. Int J Hematol 67:123-129.1998
5) Peters Rw, McQuillan S, Resnick SK et al:Increased monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation 94:1346-1349,1996
6) Shiotani I. Sato H. Kurotobi T et al:A unique business custom triggers myocardial infarction under economic recession. Circulation 100 (suppl I):1-851.1999
7) Tuininga YS. Crijns HJGM, Brouwer J et al:Evaluation of Importtance of Central Effects of Atenolol and Mctoprolol Measured by Heart Rate Variability During Mental Performance Tasks, Physical Exercise. and Daily Life in Stable Postinfarct Patients. Circulation 92:3415-3423.1995
8) Lampert R. Jain D. Burg MM et al:Destabilizing effects of mental stress on venticular arrhvthmias in patients with implantable cardioverter-defibrillators. Circulation 101:158-164.2000
9) Toivonen L, Helenius K, Viitasalo M:Electrocardiographic repolarization during stress from awakening on alarm call. J Am Coll Cardiol 30:774-779,1997
13) schwartz PJ:The idiopathic long QT syndrome:The need for a prospective registry. Eur Heart J 4:529-531,1983
15) Complon SJ, Lux RL, Ramsey MR et al:Genetically defined therapy of inherited long-QT syndrome. Correction of al,nornlal repolarization by potassium. Circulation 94:1018-1022.1996
16) Tofler G, Stone PH. Maclure M et al:Analysis of possible triggers of acute myocardial infarction (The MILIS sludy).Am J Cardiol 66:22-27,1990
18) Grignani G Soffiantino F, Zucchella M et al:Platelet activation by enlotional stress in Patients with coronary artery disease. Circulation 83 (suppl II):II-128-II-136.1991
20) Thames MD, Donald DE, Shephcrd JT:Behavior of cardiac receptors with nonmyelinated vagal afferents during spontaneous respiration in cats. Circ Res 41:694-701.1977
21) Thoren PN:Characteristics on left ventricular receptors with nonmedullated vagal afferents in cals. Circ Res 40:415-421,1977
17}Saito K. Kim JL Maekawa K et al:The great Hanshin-Awaji earthquake aggravates blood pressure control in treated hypertensive patients. Am J Hypertens 10:217-221.1997

Part 12 / β遮断薬使用上の注意点

P.288 掲載の参考文献
1) 清水昭彦,松崎益徳:β遮断薬の上手な使い方と副作用. 循環科学 1106-1109, 1997
2) 宇佐美等:β遮断薬の副作用と対処法. 小児内科 25:345-349, 1993
3) Shanes JG:β-blockade rational or irrational therapy for congestive heart failure? Circulation 76:971-973, 1987
4) Packer M, Bristow MR, Cohn J et al:The effec of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355, 1996
5) Kostis JB, Rosen RC:Central nervous system effects of β-adrenergic blocking drugs:the role orancillary Properties. Circulation 75:204-212, 1987
8) Ebstein M, Oster JR:Beta-blocker and the kidney. Mineral Electrolyte Metab 8:237-254.1995
9) Kohno M, Murakawa K, Okamura M et al:Effects of long-term administration of Carvedilol on renal haemodynamics and functions in DOCA salt-induced accelerated hypertension of spotaneneously hypertensive rats. Drugs 36 (suppl 6):S165-S168.1988
10) Vincent HH, Man-in't-Veld AJ. Boomsma F et al:Prevention of epincphrine induced hypokalemia by non selected beta blockers. Am J Cardiol 56:100-140, 1985
11) Cottrill CM. McAllister RG Jr. Gettes L et al:Propromolol therapy during Pregnancy, labor and delivery:evidence for transplacental drug trainsfer and impaired neonatal drug disposition.J Pediatr 91:812-814, 1977
12) Haraldsson A, Geven W:Severe adverse effects of maternal labetalol in a premature infant. Acta Pediatr Scand 78:956-958, 1989
13) Schmimmel MA, Eidelinan AJ. Wilschanski MA et al:Toxic effects or atcnolol consumed during breast feeding. J Pediatr 114:476-478.1989
15) Marshall AJ, Baddeley H, Barritt DW et al:Practolol peritonitis. Q J Med 46:135-149, 1977
16) Harty RF:Sclerosing peritonitis and propromolol. Ach Intern Med 138:1424-1426, 1978
P.292 掲載の参考文献
2) Arandomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765-1773, 1994
3) MERIT-HF Study Group:Effec of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007. 1999
5) Majumdar SR:Beta-blockers for the treatment of hypertension in patients with diabetes:exploring the contraindication myth. Cardiovasc Drugs Ther 13:435-439, 1999
8) Messerli FH, Grossman E, Goldbourt U:Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 279:1903-1907 1998
9) 日和田邦男, 荻原俊男:厚生省研究班「老年者の高血圧治療ガイドライン1999改訂版」. 日老医会誌36:576-603, 1999
P.298 掲載の参考文献
1) Guidelines Subcommittee:1999 WHO-ISH hypertension guidelines for the management of hyper tension. J Hypertenses 17:151-183.1999
3) Kostis JB, Bcrge KG. Davis BR et at:Effect of atcnolol and reserpine on selected events in the Systolic Hypertension in the Elderly Program (SHEP). Am J Hypertens 8:1147-1153.1995
4) Hansson L:Beta-blockers with ACE inhibitors-a logical combination? J Hum Hypertens 3:97-100. 1989
5) Belz GG:Beta-blockers and ACE inhibitors. In:Comibination Drug Therapy for Hypertension. ed by Opie LH. Messerli FH, Authors' Publishing House, New York. 1997, pp 77-90
6) Belz GG, Breithaupt K. Erb K et al:Influence of thc ACE inhibitor cilazapril, the β-blocker propranolol and their combin on haemodynamics in hypertension.J Hypertense 7:817-824.1989
7) 古家恵子, 越前宏俊:降圧薬と薬物相互作用一覧表. 血圧4:703-716, 1997
8) 大屋裕輔, 阿部功:心疾患合併例における薬物相互作用. 相互作用4:661-667, 1997
10) Shorr RI, Ray WA. Daugherty JR et al:Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfollylureas. JAMA 278:40-43, 1997
11) Miners JO. Wing LM, Lillywhite KJ et al:Selectivily and dose-dependency or the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol 20:219-223.1985
12) 瀧下修一:薬物相互作用と降圧薬療法.最新医学 (臨時増刊) 51:721-731.1996
13) 板橋繁, 佐々木英忠:呼吸器疾患例における薬物相互作用. 血圧4:668-672.1997

最近チェックした商品履歴

Loading...